Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
Ann Williams Graham J. Hatch Simon O. Clark Karen E. Gooch Kim A. Hatch Graham A. Hall Kris Huygen Tom H.M. Ottenhoff Kees L.M.C. Franken Peter Andersen T. Mark Doherty Stefan H.E. Kaufmann Leander Grode Peter Seiler Carlos Martin Brigitte Gicquel Stewart T. Cole Priscille Brodin Alexander S. Pym Wilfried Dalemans Joe Cohen Yves Lobet Nilu Goonetilleke Helen McShane Adrian Hill Tanya Parish Debbie Smith Neil G. Stoker Douglas B. Lowrie Gunilla Källenius Stefan Svenson Andrzej Pawlowski Karen Blake Philip D. Marsh
Tuberculosis (Edinburgh, Scotland), 2005
https://doi.org/10.1016/j.tube.2004.09.009
Andrzej Pawlowski
Pawlowski Andrzej
ORCID: 0000-0003-4555-6048
Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells. 10.1371/journal.pone.0042515
Mycobacterium tuberculosis infection interferes with HIV vaccination in mice. 10.1371/journal.pone.0041205
Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection. 10.1002/eji.201142049
Tuberculosis and HIV co-infection. 10.1371/journal.ppat.1002464
Failure to recruit anti-inflammatory CD103+ dendritic cells and a diminished CD4+ Foxp3+ regulatory T cell pool in mice that display excessive lung inflammation and increased susceptibility to Mycobacterium tuberculosis. 10.1128/IAI.05552-11
Mannosylated lipoarabinomannan balances apoptosis and inflammatory state in mycobacteria-infected and uninfected bystander macrophages. 10.1016/j.micpath.2011.03.004
Mycobacterium tuberculosis lipoarabinomannan enhances LPS-induced TNF-α production and inhibits NO secretion by engaging scavenger receptors. 10.1016/j.micpath.2011.03.001
Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. 10.1371/journal.pone.0016647
Mycobacterial glycoconjugates as vaccine candidates against tuberculosis. 10.1016/j.tim.2008.07.007
Should a new tuberculosis vaccine be administered intranasally? 10.1016/j.tube.2006.12.006
Low dose chronic Schistosoma mansoni infection increases susceptibility to Mycobacterium bovis BCG infection in mice. 10.1111/j.1365-2249.2004.02719.x
Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. 10.1016/j.vaccine.2004.09.038
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. 10.1016/j.tube.2004.09.013
A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. 10.1111/j.1365-2249.2004.02593.x
Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. 10.1016/j.vaccine.2003.10.016
Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. 10.1016/S0264-410X(03)00274-3
Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. 10.1016/S0167-7012(01)00239-1
Preparation of pneumococcal capsular polysaccharide-protein conjugate vaccines utilizing new fragmentation and conjugation technologies. 10.1016/S0264-410X(99)00336-9
Electron beam fragmentation of bacterial polysaccharides as a method of producing oligosaccharides for the preparation of conjugate vaccines. 10.1111/j.1574-6968.1999.tb13577.x
A new method of non-cross-linking conjugation of polysaccharides to proteins via thioether bonds for the preparation of saccharide-protein conjugate vaccines. 10.1016/S0264-410X(98)00385-5
Effects of IGF-I, rGH, FGF, EGF and NCS on DNA-synthesis, cell proliferation and morphology of chondrocytes isolated from rat rib growth cartilage. 10.1016/0309-1651(89)90148-3
Effects of IGF-I, EGF, and FGF on proteoglycans synthesized by fractionated chondrocytes of rat rib growth plate. 10.1016/0014-4827(88)90287-X
Cell fractions from rat rib growth cartilage. Biochemical characterization of matrix molecules. 10.1016/0014-4827(86)90468-4
Experimental desquamation of intestinal epithelium for in vivo studies of regeneration. 10.1007/BF01964023
simon clark
clark simon
ORCID: 0000-0003-1923-6120
Construction of a severely attenuated mutant of Mycobacterium tuberculosis for reducing risk to laboratory workers 10.1016/j.tube.2008.02.008
Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs 10.1111/j.1365-2567.2004.01809.x
Revaccination of Guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG's protection against tuberculosis 10.1093/infdis/jix030
Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs 10.1128/IAI.73.6.3814-3816.2005
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) with mycobacterium tuberculosis strain H37RV 10.1016/j.jcpa.2013.05.005
Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing 10.1128/CVI.00079-10
An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques 10.1371/journal.pone.0171906
Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology 10.1111/j.1365-2249.2004.02648.x
Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis 10.1038/s41598-019-54108-y
Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease 10.1038/s41598-017-10234-z
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein 10.1016/j.vaccine.2009.09.007
Protective efficacy of inhaled BCG vaccination against ultra-low dose aerosol M. Tuberculosis challenge in rhesus macaques 10.3390/pharmaceutics12050394
Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix 10.1371/journal.pone.0087329
Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis 10.1016/j.vaccine.2017.01.079
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection 10.1016/j.micinf.2008.09.004
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis 10.1016/j.vaccine.2019.11.085
Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy 10.1007/978-1-4939-7638-6_4
Evaluation of the immunogenicity of Mycobacterium bovis BCG delivered by aerosol to the lungs of macaques 10.1128/CVI.00289-15
Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques 10.1016/j.tube.2015.10.004
Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination 10.1016/j.vaccine.2010.07.087
Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface 10.1016/j.trivac.2015.03.003
The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs 10.1016/j.vaccine.2006.03.017
Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway 10.12688/wellcomeopenres.10036.1
Assessment of mycobacterium bovis deleted in p27-p55 virulence operon as candidate vaccine against tuberculosis in animal models 10.1155/2014/951978
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials 10.1016/j.vaccine.2013.07.051
Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge 10.1016/j.vaccine.2006.05.025
Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of Mycobacterium tuberculosis infection in rhesus macaques 10.1016/j.tube.2015.11.004
Use of high frequency jet ventilation as a refinement for imaging macaques with respiratory disease 10.1177/0023677220913328
Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guérin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis 10.1128/IAI.00052-08
Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2006.01.014
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Animal models of tuberculosis: Guinea pigs 10.1101/cshperspect.a018572
Correlates between models of virulence for Mycobacterium tuberculosis among isolates of the Central Asian Lineage: A case for lysozyme resistance testing? 10.1128/IAI.03080-14
Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis 10.1016/j.tube.2009.09.002
Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis 10.1016/j.vaccine.2008.08.028
Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies 10.1016/j.tube.2018.10.013
Induction of high levels of protective immunity in mice after vaccination using dendritic cells infected with auxotrophic mutants of Mycobacterium tuberculosis 10.1016/j.imlet.2005.10.011
Construction and characterization of the mycobacterium tuberculosis sigE fadD26 unmarked double mutant as a vaccine candidate 10.1128/IAI.00496-19
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells 10.1016/j.vaccine.2008.10.034
Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis 10.1016/j.vaccine.2015.01.058
The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs 10.1016/j.vaccine.2014.05.005
Survival of Mycobacterium tuberculosis during experimental aerosolization and implications for aerosol challenge models 10.1111/j.1365-2672.2011.05069.x
Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases 10.1164/rccm.201110-1769OC
TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development 10.3389/fimmu.2017.01203
Intranasal IFNγ extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection 10.1111/j.1365-2249.2006.03012.x
Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations 10.1016/j.tube.2016.09.004
Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses 10.1111/cmi.12065
Helen McShane
McShane Helen
ORCID: 0000-0002-2126-5142
Email: helen.mcshane@ndm.ox.ac.uk
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. 10.12688/f1000research.51640.1
Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults. 10.3390/vaccines9040396
Lessons from the pandemic on the value of research infrastructure. 10.1186/s12961-021-00704-2
Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. 10.1016/j.vaccine.2021.01.034
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates. 10.1038/s41541-020-00263-7
Markers of achievement for assessing and monitoring gender equity in a UK National Institute for Health Research Biomedical Research Centre: A two-factor model. 10.1371/journal.pone.0239589
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. 10.3389/fimmu.2019.02983
Identification of antigens presented by MHC for vaccines against tuberculosis. 10.1038/s41541-019-0148-y
Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen. 10.1016/j.vaccine.2019.11.005
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults. 10.1016/j.vaccine.2019.10.102
COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. 10.1017/s0033291720005188
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. 10.1172/jci.insight.130090
Nitric Oxide Modulates Metabolic Remodeling in Inflammatory Macrophages through TCA Cycle Regulation and Itaconate Accumulation. 10.1016/j.celrep.2019.06.018
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. 10.1371/journal.pmed.1002790
Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. 10.1016/j.jim.2019.01.006
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. 10.12688/wellcomeopenres.14736.1
Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection. 10.3389/fimmu.2018.02893
Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin. 10.1038/s41467-018-07714-9
Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1- CD4+ T cells. 10.1038/s41385-018-0109-1
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection. 10.1038/s41598-018-32755-x
Induction and maintenance of a phenotypically heterogeneous lung tissue-resident CD4+ T cell population following BCG immunisation. 10.1016/j.vaccine.2018.07.035
Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. 10.1371/journal.pone.0201205
WHO preferred product characteristics for new vaccines against tuberculosis. 10.1016/s1473-3099(18)30421-3
Elevated IgG responses in infants are associated with reduced prevalence of mycobacterium tuberculosis infection. 10.3389/fimmu.2018.01529
Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine. 10.1128/iai.00014-18
Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosis-Specific T-Cell Responses. 10.1093/infdis/jiy052
Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. 10.1093/cid/cix834
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines. 10.1016/j.tube.2017.11.006
Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model. 10.1371/journal.pone.0191038
Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals. 10.1111/tmi.13009
Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials. 10.1371/journal.pone.0184391
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development. 10.1016/j.tube.2017.07.008
The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010-2014. 10.1128/cvi.00142-17
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination. 10.5588/ijtld.16.0709
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. 10.1371/journal.pntd.0005440
Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. 10.1016/s2213-2600(17)30060-7
Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods. 10.1128/cvi.00525-16
Replacing, reducing and refining the use of animals in tuberculosis vaccine research. 10.14573/altex.1607281
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. 10.1038/srep43478
Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology. 10.3390/ijms18020312
In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. 10.1016/j.vaccine.2016.07.058
A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis. 10.1186/s12879-016-1751-4
Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction. 10.1093/infdis/jiw141
Human newborn bacille Calmette-Guérin vaccination and risk of tuberculosis disease: a case-control study. 10.1186/s12916-016-0617-3
T-cell activation is an immune correlate of risk in BCG vaccinated infants. 10.1038/ncomms11290
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. 10.1016/j.vaccine.2016.01.062
Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity. 10.1093/infdis/jiv482
Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. 10.1016/j.tube.2015.10.002
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. 10.1016/j.ebiom.2015.09.027
Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. 10.1016/j.vaccine.2015.10.017
Evaluation of Xpert® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. 10.1371/journal.pone.0141623
A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. 10.1371/journal.pone.0141687
The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. 10.1097/inf.0000000000000847
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. 10.1097/inf.0000000000000874
Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. 10.1371/journal.pone.0138042
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. 10.1016/s2213-2600(15)00037-5
Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model. 10.1093/infdis/jiu615
The association between the ratio of monocytes: lymphocytes and risk of tuberculosis among HIV-infected postpartum women. 10.1097/qai.0000000000000353
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. 10.1186/s12879-014-0660-7
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. 10.1016/s1473-3099(14)70845-x
Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. 10.1182/blood-2014-04-568691
Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle. 10.1016/j.vaccine.2014.08.009
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life. 10.1186/s12916-014-0120-7
Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. 10.1128/cvi.00128-14
Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. 10.1186/1471-2334-14-314
Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. 10.1016/j.tube.2013.12.006
Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. 10.1371/journal.pone.0097366
Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting. 10.1016/j.vetimm.2014.01.010
Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination. 10.1093/infdis/jit647
Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. 10.1016/j.vaccine.2013.11.045
The candidate TB vaccine, MVA85A, induces highly durable Th1 responses. 10.1371/journal.pone.0087340
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. 10.1093/infdis/jit494
A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression. 10.1371/journal.pone.0081317
Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG. 10.1128/cvi.00427-13
Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice. 10.1371/journal.pone.0078312
Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb). 10.1016/j.tube.2013.04.007
Heterologous vaccination against human tuberculosis modulates antigen-specific CD4+ T-cell function. 10.1002/eji.201343454
Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. 10.4161/hv.24998
Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. 10.1371/journal.pone.0067922
Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. 10.1371/journal.pone.0067177
Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. 10.1128/cvi.00690-12
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. 10.1016/s0140-6736(13)60177-4
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. 10.1016/j.vaccine.2012.12.042
Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. 10.1016/j.tube.2013.01.003
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. 10.4161/hv.22464
Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. 10.1371/journal.pone.0050447
Incidental diagnosis in healthy clinical trial subjects. 10.1111/j.1752-8062.2011.00393.x
Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. 10.1016/j.vaccine.2012.06.084
A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. 10.1016/j.vaccine.2012.06.054
A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. 10.1164/rccm.201108-1548oc
A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. 10.1093/infdis/jis012
Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A. 10.1371/journal.pone.0023463
Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy. 10.1371/journal.pone.0019840
A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. 10.1136/bmjopen-2011-000223
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. 10.1093/infdis/jir195
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. 10.1126/scitranslmed.3002461
Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses. 10.1371/journal.pone.0026434
Dual neonate vaccine platform against HIV-1 and M. tuberculosis. 10.1371/journal.pone.0020067
The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life. 10.1371/journal.pone.0012287
Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. 10.1128/cvi.00079-10
Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. 10.4049/jimmunol.1000552
Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. 10.1186/1471-2172-11-35
Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A. 10.1128/cvi.00047-10
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. 10.1002/eji.200939754
Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. 10.1371/journal.pone.0007972
Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. 10.1128/iai.00287-09
Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. 10.1371/journal.pone.0005934
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. 10.1164/rccm.200809-1486oc
Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. 10.1128/iai.00685-08
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. 10.1371/journal.pone.0005264
A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. 10.1016/j.tube.2008.06.005
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. 10.4049/jimmunol.181.7.4955
Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1. 10.1016/j.vaccine.2008.07.040
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. 10.1086/590185
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. 10.1371/journal.pone.0002921
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. 10.1371/journal.pmed.0050145
The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo. 10.1016/j.vaccine.2007.10.025
Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine models. 10.1016/j.vaccine.2007.09.065
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. 10.1002/eji.200737504
Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. 10.1371/journal.pone.0001052
Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding. 10.1128/jvi.00707-07
Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. 10.1016/s1473-3099(06)70552-7
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. 10.1016/j.vaccine.2005.08.048
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. 10.1097/01.aids.0000218545.31716.a4
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. 10.1016/j.vaccine.2005.08.041
Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. 10.1128/iai.73.6.3814-3816.2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. 10.1016/j.tube.2004.09.015
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. 10.1038/nm1128
Efficacy of follow-up and contact tracing of women who test positive for genital tract chlamydia trachomatis prior to pregnancy termination. 10.1080/01443610400008065
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. 10.1099/vir.0.19701-0
CD8+ T cell-mediated suppression of intracellular Mycobacterium tuberculosis growth in activated human macrophages. 10.1002/eji.200324109
Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. 10.4049/jimmunol.171.3.1602
Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. 10.1128/iai.70.3.1623-1626.2002
Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. 10.4049/jimmunol.167.9.5217
Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. 10.1164/ajrccm.163.4.2009100
Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. 10.1128/iai.69.2.681-686.2001
High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted Mycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. 10.1002/1521-4141(200009)30:9<2713::aid-immu2713>3.0.co;2-4
Disseminated Penicillium marneffei infection presenting as a right upper lobe mass in an HIV positive patient. 10.1136/thx.53.10.905
Local Pulmonary Immunological Biomarkers in Tuberculosis. 10.3389/fimmu.2021.640916
Towards new TB vaccines. 10.1007/s00281-020-00794-0
Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis? 10.1164/rccm.201912-2408ed
Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. 10.1080/14760584.2019.1692657
Insights and challenges in tuberculosis vaccine development. 10.1016/s2213-2600(19)30274-7
The Humoral Immune Response to BCG Vaccination. 10.3389/fimmu.2019.01317
Current approaches toward identifying a correlate of immune protection from tuberculosis 10.1080/14760584.2019.1552140
VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy. 10.12688/f1000research.14386.1
Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK. 10.12688/f1000research.14476.2
Progress and challenges in TB vaccine development. 10.12688/f1000research.13588.1
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. 10.3389/fimmu.2017.01203
Antibodies and tuberculosis. 10.1016/j.tube.2016.08.001
TB vaccines in clinical development. 10.1016/j.tube.2016.05.013
Why don't we have an effective tuberculosis vaccine yet? 10.1586/14760584.2016.1170599
A review of clinical models for the evaluation of human TB vaccines. 10.1080/21645515.2015.1134407
Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. 10.1093/ije/dyw058
From AIDS to TB vaccines--A career in infectious diseases and translational vaccinology. 10.1080/21645515.2015.1100912
The human immune response to tuberculosis and its treatment: a view from the blood. 10.1111/imr.12269
Aerosol immunisation for TB: matching route of vaccination to route of infection. 10.1093/trstmh/tru206
TB vaccine development: where are we and why is it so difficult? 10.1136/thoraxjnl-2014-205202
A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. 10.1016/j.tube.2013.11.003
Understanding BCG is the key to improving it. 10.1093/cid/cit793
Tuberculosis vaccine trials - Authors' reply. 10.1016/s0140-6736(13)61483-x
Vaccination against tuberculosis: how can we better BCG? 10.1016/j.micpath.2012.12.002
Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents. 10.1016/j.tube.2012.11.005
BCG: myths, realities, and the need for alternative vaccine strategies. 10.1016/j.tube.2011.12.003
Tuberculosis vaccines: beyond bacille Calmette-Guerin. 10.1098/rstb.2011.0097
Tuberculosis vaccines: progress and challenges. 10.1016/j.tips.2011.06.003
Tuberculosis vaccine promises sterilizing immunity. 10.1038/nm.2503
Tuberculosis vaccines in clinical trials. 10.1586/erv.11.28
A New Vaccine for Tuberculosis: The Challenges of Development and Deployment. 10.1007/s11673-009-9153-6
Vaccine strategies against tuberculosis. smw-12374
Tuberculosis vaccines: present and future. 10.1586/17476348.2.6.721
Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis. 10.1111/j.1365-2249.2006.03306.x
Tuberculosis vaccines: current status and future prospects. 10.1517/14728214.11.2.207
New TB vaccine granted orphan drug status. 10.1136/bmj.331.7530.1476
Prime-boost immunisation strategies for tuberculosis. 10.1016/j.micinf.2005.03.009
Co-infection with HIV and TB: double trouble. 10.1258/0956462053057576
Developing an improved vaccine against tuberculosis. 10.1586/14760584.3.3.299
Susceptibility to tuberculosis--the importance of the pathogen as well as the host. 10.1046/j.1365-2249.2003.02194.x
Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. 10.1016/s2468-2667(21)00096-7
The next 10 years for tuberculosis vaccines: do we have the right plans in place? 10.1586/erv.13.19
Equity for excellence in academic institutions: a manifesto for change [version 1; peer review: 2 approved] 10.12688/wellcomeopenres.16861.1
Injection fears and COVID-19 vaccine hesitancy. 10.1017/s0033291721002609
High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation. 10.1038/s41598-021-90913-0
SARS-CoV-2 Human Challenge Studies - Establishing the Model during an Evolving Pandemic. 10.1056/nejmp2106970
Induction of specific antibodies, IgG-secreting plasmablasts and memory B cells following BCG vaccination 10.1101/2021.02.18.431837
Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA) 10.1101/2021.02.14.431105
Alexander Pym
Pym Alexander
ORCID: 0000-0002-6260-8180
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. 10.1016/S0140-6736(14)62002-X
Effective anti-tuberculosis therapy correlates with plasma small RNA. 10.1183/09031936.00221214
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. 10.1186/2050-6511-15-61
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. 10.1056/NEJMoa1407426
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. 10.1128/JCM.02438-14
Multidrug-resistant tuberculosis and culture conversion with bedaquiline. 10.1056/NEJMoa1313865
[In Process Citation]. 10.1016/S0399-077X(14)70062-9
Selection of RNA aptamers against the M. tuberculosis EsxG protein using surface plasmon resonance-based SELEX. 10.1016/j.bbrc.2014.04.163
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. 10.1016/S1473-3099(14)70733-9
High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission. 10.1371/journal.pone.0090868
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. 10.1371/journal.pone.0084866
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. 10.1016/S2213-2600(13)70231-5
High-throughput sequencing enhanced phage display identifies peptides that bind mycobacteria. 10.1371/journal.pone.0077844
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. 10.1016/S0140-6736(13)62073-5
Consensus standards for introductory e-learning courses in human participants research ethics. 10.1136/medethics-2013-101572
EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. 10.1186/1471-2458-13-258
Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. 10.5588/ijtld.12.0017
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. 10.1073/pnas.1203636109
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. 10.1128/AAC.05526-11
Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. 10.1128/AAC.06126-11
International spread of MDR TB from Tugela Ferry, South Africa. 10.3201/eid1711.110291
Drug-Resistant tuberculosis, KwaZulu-Natal, South Africa, 2001-2007. 10.3201/eid1710.100952
Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. 10.1056/NEJMoa0808427
Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. 10.1371/journal.pone.0002363
Challenges in estimating the total burden of drug-resistant tuberculosis. 10.1164/rccm.200801-175PP
Safety of nevirapine in pregnancy. 10.1111/j.1468-1293.2007.00433.x
Evaluation of new antituberculosis drugs in mouse models. 10.1128/AAC.01246-06
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. 10.1371/journal.ppat.0020061
Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. 10.1128/JCM.43.7.3185-3191.2005
Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis? 10.1128/JCM.43.7.3530-3532.2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
High-throughput method for detecting genomic-deletion polymorphisms. 10.1128/JCM.42.7.2913-2918.2004
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859
Proteome analysis of the plasma membrane of Mycobacterium tuberculosis. 10.1002/cfg.211
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x
Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. 10.1128/IAI.70.9.4955-4960.2002
A new evolutionary scenario for the Mycobacterium tuberculosis complex. 10.1073/pnas.052548299
Inactivation of the Mycobacterium tuberculosis Nramp orthologue (mntH) does not affect virulence in a mouse model of tuberculosis. 10.1111/j.1574-6968.2002.tb11032.x
The evolution of mycobacterial pathogenicity: clues from comparative genomics. 10.1016/S0966-842X(01)02131-X
Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. 10.1046/j.1365-2958.2001.02427.x
Tools for the population genomics of the tubercle bacilli. 10.1101/gr.169200
Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. 10.1002/1097-0061(20000630)17:2<111::AID-YEA17>3.0.CO;2-G
The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. 10.1089/088922299310278
The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients. 10.1089/088922299311079
Post DOTS, post genomics: the next century of tuberculosis control. 10.1016/S0140-6736(99)02118-2
Disease progression and survival in HIV-1-infected Africans in London. 10.1097/00002030-199810000-00013
Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. 10.1097/00002030-199809000-00006
Pasteurella multocida abcess in an African patient with human immunodeficiency virus infection. 10.1111/j.1469-0691.1997.tb00484.x
Vancouver: optimism, but at a cost. 10.1258/0956462961918257
Reasons for increased incidence of tuberculosis. Audit suggests that undernotification is common. 10.1136/bmj.311.7004.570a
Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics. 10.1016/j.ebiom.2016.05.041
Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. 10.1038/ng.3548
Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. 10.1371/journal.pone.0153143
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. 10.1093/jac/dkv470
Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. 10.1038/srep19391
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. 10.1183/13993003.00724-2015
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. 10.1128/aac.01195-15
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. 10.1371/journal.pmed.1001880
Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System. 10.1186/s12889-015-2117-3
Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. 10.5588/ijtld.14.0944
Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing. 10.1186/s12879-015-0967-z
Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study. 10.1186/s12879-015-0964-2
Fatal nosocomial MDR TB identified through routine genetic analysis and whole-genome sequencing. 10.3201/eid2106.141903
Biomarkers for Tuberculosis Based on Secreted, Species-Specific, Bacterial Small Molecules. 10.1093/infdis/jiv312
Impact of tuberculosis treatment and antiretroviral therapy on serial RD-1-specific quantitative T-cell readouts (QuantiFERON-TB Gold In-Tube), and relationship to treatment-related outcomes and bacterial burden. 10.1016/j.ijid.2015.05.006
A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population. 10.1128/jcm.03530-14
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis. 10.1186/s12916-017-0947-9
Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance. 10.1128/aac.01461-17
A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. 10.1038/s41467-017-00721-2
Clofazimine protects against Mycobacterium tuberculosis dissemination in the central nervous system following aerosol challenge in a murine model. 10.1016/j.ijantimicag.2017.08.020
Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. 10.5588/ijtld.16.0843
Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells. 10.7554/elife.22028
Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. 10.1038/ng.3767
Dual-Reporter Mycobacteriophages (Φ2DRMs) Reveal Preexisting Mycobacterium tuberculosis Persistent Cells in Human Sputum. 10.1128/mbio.01023-16
Neil Stoker
Stoker Neil / Neil G. Stoker
ORCID: 0000-0001-7055-6184
Tuberculosis in a changing world 10.1136/bmj.309.6963.1178
amiA is a negative regulator of acetamidase expression in Mycobacterium smegmatis 10.1186/1471-2180-1-1
Construction of a severely attenuated mutant of Mycobacterium tuberculosis for reducing risk to laboratory workers 10.1016/j.tube.2008.02.008
Identification and characterization of the human type II collagen gene (COL2A1) 10.1073/pnas.82.9.2555
Transmission of tuberculosis in British centre for patients infected with HIV 10.1136/bmj.309.6955.639
Mutational analysis of the regulatory region of the Mycobacterium plasmid pAL5000 10.1093/nar/25.19.3840
The polymerase chain reaction and infectious diseases: Hopes and realities 10.1016/0035-9203(90)90064-L
Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis 10.1128/IAI.71.3.1134-1140.2003
Analysis of whole-genome microarray replicates using mixed models 10.1093/bioinformatics/19.1.53
Clinical use of whole genome sequencing for Mycobacterium tuberculosis 10.1186/s12916-016-0598-2
Gene replacement in mycobacteria by using incompatible plasmids 10.1128/AEM.69.1.517-523.2003
The Mycobacterium tuberculosis sigJ gene controls sensitivity of the bacterium to hydrogen peroxide 10.1016/j.femsle.2004.07.005
The case for hypervirulence through gene deletion in Mycobacterium tuberculosis 10.1016/j.tim.2008.06.003
A universally applicable method of operon map prediction on minimally annotated genomes using conserved genomic context 10.1093/nar/gki634
Mycobacterial cells have dual nickel-cobalt sensors: Sequence relationships and metal sites of metal-responsive repressors are not congruent 10.1074/jbc.M703451200
Microarray analysis of bacterial gene expression: Towards the regulome 10.1002/cfg.193
Cholesterol utilization in mycobacteria is controlled by two TetR-type transcriptional regulators: kstR and kstR2 10.1099/mic.0.034538-0
Investigating the function of the putative mycolic acid methyltransferase UmaA: Divergence between the mycobacterium smegmatis and mycobacterium tuberculosis proteins 10.1074/jbc.M708859200
Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essentiality 10.1054/tube.2001.0312
The Mycobacterium tuberculosis dosRS two-component system is induced by multiple stresses 10.1016/j.tube.2003.12.007
Lipid composition and transcriptional response of Mycobacterium tuberculosis grown under iron-limitation in continuous culture: Identification of a novel wax ester 10.1099/mic.0.2006/004317-0
Transcriptome Analysis: Towards a Comprehensive Understanding of Global Transcription Activity 10.1002/352760801X.ch2
Tuberculous pericarditis confirmed by DNA amplification 10.1016/0140-6736(91)90840-L
The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction 10.1111/j.1462-5822.2007.01097.x
Development and use of a conditional antisense mutagenesis system in mycobacteria 10.1016/S0378-1097(97)00317-0
Experimental determination of translational starts using peptide mass mapping and tandem mass spectrometry within the proteome of Mycobacterium tuberculosis 10.1099/mic.0.2006/001537-0
Rapid construction of mycobacterial mutagenesis vectors using ligation-independent cloning 10.1016/j.mimet.2010.07.014
Cloning of mycobacterial histidine synthesis genes by complementation of a Mycobacterium smegmatis auxotroph 10.1111/j.1365-2958.1992.tb01468.x
Versatile low-copy-number plasmid vectors for cloning in Escherichia coli 10.1016/0378-1119(82)90172-X
Genome sequencing and characterization of an extensively drug-resistant sequence type 111 serotype O12 hospital outbreak strain of Pseudomonas aeruginosa 10.1111/1469-0691.12528
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
RNA profiling in host-pathogen interactions 10.1016/j.mib.2007.05.013
A highly conserved transcriptional repressor controls a large regulon involved in lipid degradation in Mycobacterium smegmatis and Mycobacterium tuberculosis 10.1111/j.1365-2958.2007.05827.x
High level expression of genes cloned in phage λgt11 10.1016/0378-1119(89)90317-X
An Escherichia coli-Mycobacterium shuttle cosmid vector, pMSC1 10.1016/0378-1119(92)90453-V
BμG@Sbase - A microbial gene expression and comparative genomic database 10.1093/nar/gkr796
A derivative of Mycobacterium smegmatis mc2155 that lacks the duplicated chromosomal region 10.1016/j.tube.2005.10.001
Deletion of the Mycobacterium tuberculosis α-crystallin-like hspX gene causes increased bacterial growth in vivo 10.1128/IAI.74.2.861-868.2006
glnE is an essential gene in Mycobacterium tuberculosis 10.1128/JB.182.20.5715-5720.2000
Transmission of tuberculosis in patients with HIV infection 10.1136/bmj.310.6976.401
Inositol monophosphate phosphatase genes of Mycobacterium tuberculosis 10.1186/1471-2180-10-50
bkaR is a TetR-type repressor that controls an operon associated with branched-chain keto-acid metabolism in Mycobacteria 10.1111/1574-6968.12196
Cholesterol metabolism in Mycobacterium smegmatis 10.1111/j.1758-2229.2011.00314.x
Use of polymerase chain reaction to assess efficacy of leprosy chemotherapy 10.1016/0140-6736(93)91816-5
Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates 10.1128/IAI.69.2.1442-1150.2001
Aspects of tuberculosis in africa. 3. genetic ‘fingerprinting’ for clues to the pathogenesis of tuberculosis 10.1016/0035-9203(92)90072-K
Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases 10.1128/JCM.02993-14
What do microarrays really tell us about M. tuberculosis? 10.1016/j.tim.2004.10.005
Tropist3: a cosmid vector for simplified mapping of both G + C-rich and A + T-rich genomic DNA 10.1016/0378-1119(93)90467-H
A GAF domain in the hypoxia/NO-inducible Mycobacterium tuberculosis DosS protein binds haem 10.1016/j.jmb.2005.09.011
Crystal structure of inositol 1-phosphate synthase from Mycobacterium tuberculosis, a key enzyme in Phosphatidylinositol Synthesis 10.1016/S0969-2126(02)00718-9
Inactivation of mycobacteriophage D29 using ferrous ammonium sulphate as a tool for the detection of viable Mycobacterium smegmatis and M. tuberculosis 10.1016/S0923-2508(98)80003-X
The Mycobacterium tuberculosis Rv1099c gene encodes a GlpX-like class II fructose 1,6-bisphosphatase 10.1099/mic.0.27204-0
Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages 10.1371/journal.pone.0001403
Role of the DinB homologs Rv1537 and Rv3056 in Mycobacterium tuberculosis 10.1128/JB.01135-09
Polymerase chain reaction for detection of Mycobacterium tuberculosis in sputum 10.1007/BF01992166
Quantification of global transcription patterns in prokaryotes using spotted microarrays 10.1186/gb-2007-8-12-r265
The Mycobactenum tuberculosis ino1 gene is essential for growth and virulence 10.1046/j.1365-2958.2003.03900.x
DNA fingerprints of Mycobacterium tuberculosis do not change during the development of rifampicin resistance 10.1016/0962-8479(93)90049-4
The influence of reduced oxygen availability on pathogenicity and gene expression in Mycobacterium tuberculosis 10.1016/j.tube.2003.12.011
Whole genome comparison of Campylobacter jejuni human isolates using a low-cost microarray reveals extensive genetic diversity 10.1101/gr.185801
Screening of highly expressed mycobacterial genes identifies Rv3615c as a useful differential diagnostic antigen for the Mycobacterium tuberculosis complex 10.1128/IAI.00150-08
A highly polymorphic region 3′ to the human type II collagen gene 10.1093/nar/13.13.4613
Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses 10.1111/cmi.12065
Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection 10.1016/0962-8479(94)90008-6
Mycobacterium Tuberculosis Protocols 10.1385/1592591477
Mycobacteria Protocols 10.1385/0896034712
Mycobacteria: Bugs and Bugbears 10.1385/0-89603-471-2:1
Electroporation of Mycobacteria 10.1385/0-89603-471-2:129
Mycobacteria: Biology 10.1002/9780470015902.a0020389
Gene Replacement Systems† 10.1128/9781555817657.ch12
The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis 10.1099/00221287-148-10-3069
Development and use of a conditional antisense mutagenesis system in mycobacteria 10.1111/j.1574-6968.1997.tb12637.x
Mycobacteria: Bugs and Bugbears (Two steps forward and one step back) 10.1385/mb:13:3:191
Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement 10.1099/00221287-146-8-1969
Production of mutants in amino acid biosynthesis genes of Mycobacterium tuberculosis by homologous recombination 10.1099/00221287-145-12-3497
The Mycobacterium tuberculosis sigJ gene controls sensitivity of the bacterium to hydrogen peroxide 10.1111/j.1574-6968.2004.tb09725.x
Pathogen genomics: Impact on human health 10.1016/s0035-9203(03)90054-x
Screening gene expression libraries for epitopes recognized inMycobacterium leprae by mouse T cells 10.1002/eji.1830211047
Mycobacterial recA is cotranscribed with a potential regulatory gene called recX 10.1046/j.1365-2958.1997.3441697.x
How new technology affects the research process: The impact of CRISPR 10.6084/m9.figshare.4644403.v1
Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial 10.1186/s12916-017-0834-4
Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. 10.1186/s12941-020-00363-1
The impact of COVID-19 on global tuberculosis control. 10.4103/ijmr.ijmr_326_21
Stefan HE Kaufmann
Kaufmann Stefan HE / Stefan HE Kaufmann / Stefan Hugo Ernst Kaufmann
ORCID: 0000-0001-9866-8268
Mycobacterium Genotypes in Pulmonary Tuberculosis Infections and Their Detection by Trained African Giant Pouched Rats 10.1007/s00284-014-0705-6
Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas 10.1073/pnas.1408839111
AhR sensing of bacterial pigments regulates antibacterial defence 10.1038/nature13684
TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: 'How can big data help?' 10.1016/j.vaccine.2014.06.014
Serologic diagnosis of tuberculosis by combining Ig classes against selected mycobacterial targets 10.1016/j.jinf.2014.05.014
Dietary pyridoxine controls efficacy of vitamin b6-auxotrophic tuberculosis vaccine bacillus calmette-Guérin ΔureC::Hly Δpdx1 in Mice 10.1128/mBio.01262-14
Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states 10.1186/1471-2334-14-257
NKT cells determine titer and subtype profile of virus-specific IgG antibodies during herpes simplex virus infection 10.4049/jimmunol.1300148
TLR3 regulates mycobacterial RNA-induced IL-10 production through the PI3K/AKT signaling pathway 10.1016/j.cellsig.2014.01.015
Host-directed therapy of tuberculosis: What is in it for microRNA? 10.1517/14728222.2014.897696
CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis 10.1172/JCI72030
Analysis of protein species differentiation among mycobacterial low-Mr-secreted proteins by narrow pH range Immobiline gel 2-DE-MALDI-MS 10.1016/j.jprot.2013.06.036
Tuberculosis vaccine development at a divide 10.1097/MCP.0000000000000041
Lack of microbiota reduces innate responses and enhances adaptive immunity against Listeria monocytogenes infection 10.1002/eji.201343927
Reverse translation in tuberculosis: Neutrophils provide clues for understanding development of active disease 10.3389/fimmu.2014.00036
Antigen export during liver infection of the malaria parasite augments protective immunity 10.1128/mBio.01321-14
Type I IFN signaling triggers immunopathology in tuberculosis-susceptible mice by modulating lung phagocyte dynamics 10.1002/eji.201344219
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases 10.1038/nature12979
Combined efforts in immunology and vaccinology will lead to effective vaccines against HIV, tuberculosis and malaria 10.1111/joim.12213
Crosstalk between human DC subsets promotes antibacterial activity and CD8+ T-cell stimulation in response to bacille Calmette-Guérin 10.1002/eji.201343797
Communication between human dendritic cell subsets in tuberculosis: Requirements for naive CD4+ T cell stimulation 10.3389/fimmu.2014.00324
Recent advances towards tuberculosis control: Vaccines and biomarkers 10.1111/joim.12212
Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review 10.1016/S2213-2600(14)70033-5
Tumor necrosis factor alpha in mycobacterial infection 10.1016/j.smim.2014.04.003
Vaccination against tuberculosis: Time to think about the next generation vaccinations | Impfung gegen tuberkulose: Zeit, an die nächste impfstoffgeneration zu denken 10.1007/s10405-013-0697-0
Challenges and responses in human vaccine development 10.1016/j.coi.2014.01.009
A universal TaqMan-based RT-PCR protocol for cost-efficient detection of small noncoding RNA 10.1261/rna.040501.113
Erratum: Diagnostic biomarkers are hidden in the infected host's epigenome (Expert Review of Molecular Diagnostics (2013) 13:6 (625-637)) 10.1586/14737159.2013.845397
The tuberculosis vaccine candidate bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in mice 10.1371/journal.pone.0078966
MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment 10.1172/JCI67604
Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa 10.1371/journal.pone.0074080
Inflammation in tuberculosis: Interactions, imbalances and interventions 10.1016/j.coi.2013.05.005
The Mycobacterium tuberculosis regulatory network and hypoxia 10.1038/nature12337
Diagnostic biomarkers are hidden in the infected host's epigenome 10.1586/14737159.2013.811897
The Mtb proteome library: A resource of assays to quantify the complete proteome of mycobacterium tuberculosis 10.1016/j.chom.2013.04.008
The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis 10.1111/j.1749-6632.2012.06802.x
Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines 10.1007/s00430-012-0278-6
Tuberculosis vaccines: Time to think about the next generation 10.1016/j.smim.2013.04.006
Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial 10.1016/j.vaccine.2012.12.053
Induction of CCL8/MCP-2 by Mycobacteria through the Activation of TLR2/PI3K/Akt Signaling Pathway 10.1371/journal.pone.0056815
State of the art in vaccine development against TB 10.1183/1025448x.10015912
The recombinant tuberculosis vaccine rBCG ΔureC:: Hly+ induces apoptotic vesicles for improved priming of CD4+ and CD8+ T cells 10.1016/j.vaccine.2012.10.031
Recombinant live vaccine candidates against tuberculosis 10.1016/j.copbio.2012.03.007
Detection and treatment of subclinical tuberculosis 10.1016/j.tube.2012.06.004
Mycobacterium tuberculosis volatiles for diagnosis of tuberculosis by Cricetomys rats 10.1016/j.tube.2012.07.006
Enabling biomarkers for tuberculosis control 10.5588/ijtld.12.0246
A recombinant Bacille Calmette-Guérin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice 10.1016/j.vaccine.2011.09.054
Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients 10.1371/journal.pone.0040221
Tuberculosis vaccine development: Strength lies in tenacity 10.1016/j.it.2012.03.004
The proteasome system in infection: Impact of β5 and LMP7 on composition, maturation and quantity of active proteasome complexes 10.1371/journal.pone.0039827
APOPO's tuberculosis research agenda: Achievements, challenges and prospects http://dx.doi.org/10.4314/thrb.v14i2.5
Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice 10.1016/j.vaccine.2012.04.029
Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area 10.1371/journal.pone.0038501
Common patterns and disease-related signatures in tuberculosis and sarcoidosis 10.1073/pnas.1121072109
The Else Kröner-Fresenius Immunology Award 10.1038/ni.2285
Scaling up interventions to achieve global tuberculosis control: Progress and new developments 10.1016/S0140-6736(12)60727-2
Can the battle against tuberculosis gain from epigenetic research? 10.1016/j.tim.2012.03.002
Vaccines against tuberculosis: Where are we and where do we need to go? 10.1371/journal.ppat.1002607
Mycobacterium tuberculosis: Success through dormancy 10.1111/j.1574-6976.2012.00331.x
Mir-133b targets antiapoptotic genes and enhances death receptor-induced apoptosis 10.1371/journal.pone.0035345
Antigen 85C inhibition restricts Mycobacterium tuberculosis growth through disruption of cord factor biosynthesis 10.1128/AAC.05742-11
Ten challenges for TB biomarkers 10.1016/S1472-9792(12)70007-0
Experimental cerebral malaria develops independently of caspase recruitment domain-containing protein 9 signaling 10.1128/IAI.06033-11
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: A potential target for the treatment of Crohn's disease 10.1038/mi.2011.57
Ability of Cricetomys rats to detect Mycobacterium tuberculosis and discriminate it from other microorganisms 10.1016/j.tube.2011.11.008
The volatiles of pathogenic and nonpathogenic mycobacteria and related bacteria 10.3762/bjoc.8.31
Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis 10.1002/eji.201141548
Diagnosis of tuberculosis by trained African giant pouched rats and confounding impact of pathogens and microflora of the respiratory tract 10.1128/JCM.01199-11
Floating between the poles of pathology and protection: Can we pin down the granuloma in tuberculosis? 10.1016/j.mib.2011.10.006
Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting 10.1186/1471-2334-12-10
Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay 10.1038/gene.2011.64
Granulysin-Expressing CD4 + T cells as candidate immune marker for tuberculosis during childhood and adolescence 10.1371/journal.pone.0029367
Recombinant BCG ΔureC hly+ induces superior protection over parental bcg by stimulating a balanced combination of type 1 and type 17 cytokine responses 10.1093/infdis/jir592
Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens 10.1016/j.vaccine.2011.07.144
Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis 10.1371/journal.pone.0026938
Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosis TB patients 10.1111/j.1469-0691.2010.03326.x
Fact and fiction in tuberculosis vaccine research: 10 years later 10.1016/S1473-3099(11)70146-3
The IFN-γ-inducible GTPase, irga6, protects mice against toxoplasma gondii but not against plasmodium berghei and some other intracellular pathogens 10.1371/journal.pone.0020568
Cells as factories for humanized encapsulation 10.1021/nl200801n
Erratum: Immunogenicity and protective efficacy of prime-boost regimens with recombinant δureC hly+ Mycobacterium bovis BCG and modified Vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis 10.1128/IAI.00188-11
Impact of inducible co-stimulatory molecule (ICOS) on T-cell responses and protection against Mycobacterium tuberculosis infection 10.1002/eji.201040608
For better or for worse: The immune response against Mycobacterium tuberculosis balances pathology and protection 10.1111/j.1600-065X.2010.00994.x
Intracellular pathogens: Living in an extreme environment 10.1111/j.1600-065X.2010.01001.x
Tuberculosis vaccines-a new kid on the block 10.1038/nm0211-159
Human gene expression profiles of susceptibility and resistance in tuberculosis 10.1038/gene.2010.51
Ten years of the global Alliance for vaccines and immunization: Challenges and progress 10.1038/ni1210-1069
Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during salmonella typhimurium infection 10.1016/j.immuni.2010.10.016
Future vaccination strategies against tuberculosis: Thinking outside the Box 10.1016/j.immuni.2010.09.015
Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice 10.1172/JCI42796
Lysosomal α-Galactosidase Controls the Generation of Self Lipid Antigens for Natural Killer T Cells 10.1016/j.immuni.2010.08.003
Targeting the proteasome: Partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis 10.1136/gut.2009.203554
Novel tuberculosis vaccines on the horizon 10.1016/j.coi.2010.04.006
α-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation 10.1128/IAI.01441-09
Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis 10.1002/eji.201040299
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action 10.1016/S0140-6736(10)60554-5
New vaccines for tuberculosis 10.1016/S0140-6736(10)60393-5
Infection, inflammation, and chronic diseases: consequences of a modern lifestyle 10.1016/j.it.2010.02.003
α-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1+ cells into the liver 10.1002/eji.200939594
Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control 10.1016/j.tube.2010.03.008
The adaptor molecule CARD9 is essential for tuberculosis control 10.1084/jem.20090067
99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Lifestyle changes affecting the host-environment interface: Introduction to and Summary of the 99th Dahlem Conference held in Berlin, June 10-13 2009 10.1111/j.1365-2249.2010.04120.x
Novel tuberculosis vaccination strategies based on understanding the immune response 10.1111/j.1365-2796.2010.02216.x
A role for IL-18 in protective immunity against Mycobacterium tuberculosis 10.1002/eji.200939583
The quest for biomarkers in tuberculosis 10.1016/j.drudis.2009.10.005
Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach 10.1186/1471-2105-11-27
TLR2-, TLR4- and Myd88-independent acquired humoral and cellular immunity against Salmonella enterica serovar Typhimurium 10.1016/j.imlet.2009.10.008
Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling 10.1111/j.1365-2567.2009.03148.x
Microbes and Infection: Past, present and future 10.1016/j.micinf.2009.11.008
AIDS and Tuberculosis: A Deadly Liaison 10.1002/9783527627905
Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies 10.1002/9783527627905.ch2
Combination of host susceptibility and Mycobacterium tuberculosis virulence define gene expression profile in the host 10.1002/eji.200939615
Novel vaccination concepts on the basis of modern insights into immunology | Neue Impfstoffkonzepte auf Basis moderner Erkenntnisse der Immunologie 10.1007/s00103-009-0951-0
A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire 10.1128/CVI.00237-09
Knighting immunology 10.1038/ni1009-1037
Fine-tuning of T cell responses during infection 10.1016/j.coi.2009.07.004
Immunogenicity of novel DosR regulon-encoded candidate antigens of mycobacterium tuberculosis in three high-burden populations in Africa 10.1128/CVI.00111-09
Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis 10.1016/j.vaccine.2009.05.048
Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection 10.1371/journal.pone.0005590
Combination of host susceptibility and virulence of mycobacterium tuberculosis determines dual role of nitric oxide in the protection and control of inflammation 10.1086/597421
Identifying activated T cells in reconstituted RAG deficient mice using retrovirally transduced Pax5 deficient Pro-B cells 10.1371/journal.pone.0005115
Structural analysis reveals DNA binding properties of Rv2827c, a hypothetical protein from Mycobacterium tuberculosis 10.1007/s10969-009-9060-4
Editorial: Th17 cells 10.1016/j.micinf.2009.04.011
The day of immunology 2009. 10.1002/eji.200990013
Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly+ mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis 10.1128/IAI.00685-08
T-cell responses against tuberculin and sensitin in children with tuberculosis and non-tuberculosis mycobacterial lymphadenopathy 10.1111/j.1469-0691.2008.02084.x
Two-dimensional gel electrophoresis-based proteomics of mycobacteria 10.1007/978-1-59745-207-6_8
Immune responses to intracellular bacteria 10.1016/B978-0-323-04404-2.10025-9
Elie Metchnikoff's and Paul Ehrlich's impact on infection biology 10.1016/j.micinf.2008.08.012
News and EFIS 10.1002/eji.200890041
Anthrax lethal toxin suppresses chemokine production in human neutrophil NB-4 cells 10.1016/j.bbrc.2008.07.018
Tuberculosis in Africa: Learning from Pathogenesis for Biomarker Identification 10.1016/j.chom.2008.08.002
Safety and Immunogenicity of an Intramuscular Helicobacter pylori Vaccine in Noninfected Volunteers: A Phase I Study 10.1053/j.gastro.2008.05.054
Restricted expression of C-type lectin-like natural killer receptors by CD8 T cells in the murine small intestine 10.1111/j.1365-2567.2008.02817.x
Rational design of novel antibacterial vaccines with an emphasis on tuberculosis 10.1080/00365540802032759
Mycobacterium tuberculosis-specific CD4+, IFNγ+, and TNFα+ multifunctional memory T cells coexpress GM-CSF 10.1016/j.cyto.2008.05.002
How it all began: Microbes and Infection 120 years later 10.1016/j.micinf.2008.07.019
Immunology's foundation: The 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff 10.1038/ni0708-705
Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide 10.1111/j.1462-5822.2008.01147.x
Prevalence and predictors of positive tuberculin skin test results in a research laboratory 10.1590/S0037-86822008000400019
Bacillus anthracis: Balancing innocent research with dual-use potential 10.1016/j.ijmm.2007.09.007
X-ray structure of 4,4′-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14α-demethylase (CYP51) 10.1074/jbc.M801145200
Tuberculosis: Deadly combination 10.1038/453295a
Novel strategies to identify biomarkers in tuberculosis 10.1515/BC.2008.053
Paul Ehrlich: Founder of chemotherapy 10.1038/nrd2582
Inhibition of CD1 antigen presentation by human cytomegalovirus 10.1128/JVI.01447-07
Role of interleukin-12 in determining differential kinetics of invariant natural killer T cells in response to differential burden of Listeria monocytogenes 10.1016/j.micinf.2007.11.008
Viral danger signals control CD1d de novo synthesis and NKT cell activation 10.1002/eji.200737233
Mutation in the Transcriptional Regulator PhoP Contributes to Avirulence of Mycobacterium tuberculosis H37Ra Strain 10.1016/j.chom.2008.01.002
Starring stellate cells in liver immunology 10.1016/j.coi.2007.10.006
Different diagnostic criteria for latent tuberculosis are applied in laboratory-based research papers 10.1016/j.jinf.2007.10.009
Rational design of vaccines against tuberculosis directed by basic immunology 10.1016/j.ijmm.2007.07.004
Editorial by the Editor-in-Chief of Microbes and Infection 10.1016/j.resmic.2007.11.004
Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes 10.1002/eji.200737142
Natural killer T-cell characterization through gene expression profiling: An account of versatility bridging T helper type 1 (Th1), Th2 and Th17 immune responses 10.1111/j.1365-2567.2007.02701.x
Editorial by the Editor-in-Chief of Microbes and Infection 10.1016/j.micinf.2007.11.003
Notch signaling is activated by TLR stimulation and regulates macrophage functions 10.1002/eji.200636999
Anthrax-Euronet and beyond-challenges of scientific research on high risk agents 10.1007/978-1-4020-5808-0_11
Exploring functional genomics for the development of novel intervention strategies against tuberculosis 10.1016/j.ijmm.2007.03.003
Tuberculosis and AIDS - a devilish liaison 10.1016/j.drudis.2007.09.008
Reversible NK1.1 surface expression on invariant liver natural killer T cells during Listeria monocytogenes infection 10.1016/j.micinf.2007.09.019
Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography 10.1128/AAC.00311-07
Regional IFNγ expression is insufficient for efficacious control of food-borne bacterial pathogens at the gut epithelial barrier 10.1093/intimm/dxm075
Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis 10.1073/pnas.0703510104
The contribution of immunology to the rational design of novel antibacterial vaccines 10.1038/nrmicro1688
Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis 10.1007/s00109-007-0157-6
Reductive methylation to improve crystallization of the putative oxidoreductase Rv0765c from Mycobacterium tuberculosis 10.1107/S1744309107022506
Malnutrition and infection: Complex mechanisms and global impacts 10.1371/journal.pmed.0040115
An improved strategy for selective and efficient enrichment of integral plasma membrane proteins of mycobacteria 10.1002/pmic.200600928
Changing funding patterns in tuberculosis: Commentary 10.1038/nm0307-299
The early transcriptional response of human granulocytes to infection with Candida albicans is not essential for killing but reflects cellular communications 10.1128/IAI.01651-06
Comparative transcriptional profiling of the lung reveals shared and distinct features of Streptococcus pneumoniae and influenza A virus infection 10.1111/j.1365-2567.2006.02514.x
Striptease on glass: Validation of an improved stripping procedure for in situ microarrays 10.1016/j.jbiotec.2006.09.003
Protein identification and tracking in two-dimensional electrophoretic gels by minimal protein identifiers 10.1002/9783527610099.ch6
CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction 10.1002/9783527610099.ch8
Web-accessible proteome databases for microbial research 10.1002/9783527610099.ch4
Ito Cells Are Liver-Resident Antigen-Presenting Cells for Activating T Cell Responses 10.1016/j.immuni.2006.11.011
Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs 10.1086/508894
Structural diversity in the six-fold redundant set of acyl-CoA carboxyltransferases in Mycobacterium tuberculosis 10.1016/j.febslet.2006.11.054
Critical role of methylglyoxal and AGE in mycobacteria-induced macrophage apoptosis and activation 10.1371/journal.pone.0000029
Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis 10.1172/JCI28804
Selecting effective siRNAs based on guide RNA structure 10.1038/nprot.2006.206
Reliable amplification method for bacterial RNA 10.1016/j.jbiotec.2006.02.020
Human α-defensins neutralize toxins of the mono-ADP- ribosyltransferase family 10.1042/BJ20060425
Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Vα14+ NK1.1- T-cell subset after bacterial infection 10.1128/IAI.00311-06
RNA silencing in the struggle against disease 10.1196/annals.1348.051
Defensin: a multifunctional molecule lives up to its versatile name 10.1016/j.tim.2006.08.001
Envisioning future strategies for vaccination against tuberculosis 10.1038/nri1920
New tuberculosis vaccines approaching clinical trial - An overview 10.1016/j.ddstr.2006.05.006
Role of local pulmonary IFN-γ expression in murine allergic airway inflammation 10.1165/rcmb.2005-0293OC
Host-pathogen interactions 10.1016/j.coi.2006.05.009
Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of Rv2827c from Mycobacterium tuberculosis 10.1107/S1744309106024213
Progress in tuberculosis vaccine development 10.1016/j.coi.2006.05.016
The Mycobacterium tuberculosis LipB enzyme functions as a cysteine/lysine dyad acyltransferase 10.1073/pnas.0510436103
Impaired maturation and function of dendritic cells by mycobacteria through IL-1β 10.1002/eji.200535727
Bringing Immunology to the Classroom 10.1016/j.immuni.2006.03.010
Proteins unique to intraphagosomally grown Mycobacterium tuberculosis 10.1002/pmic.200500547
Tuberculosis: Back on the Immunologists' Agenda 10.1016/j.immuni.2006.04.003
Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis 10.1002/eji.200535496
Mycobacterium tuberculosis gene expression profiling within the context of protein networks 10.1016/j.micinf.2005.09.011
Immunology of tuberculosis and novel vaccination strategies | Immunologie der tuberkulose und neue impfstoffansätze 10.1007/s00112-005-1280-5
Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis 10.1128/IAI.74.2.1233-1242.2006
Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis 10.1016/j.immuni.2005.12.001
New insights into the function of granulomas in human tuberculosis 10.1002/path.1906
Transcriptional responses in mouse lungs induced by vaccination with Mycobacterium bovis BCG and infection with Mycobacterium tuberculosis 10.1016/j.micinf.2005.06.015
Robert Koch, the nobel prize, and the ongoing threat of tuberculosis 10.1056/NEJMp058131
Natural regulatory T cells and infection 10.1097/01.mot.0000183247.05086.22
Recent findings in immunology give tuberculosis vaccines a new boost 10.1016/j.it.2005.09.012
Design of siRNAs producing unstructured guide-RNAs results in improved RNA interference efficiency 10.1038/nbt1151
From bacteriology to immunology: The dualism of specificity 10.1038/ni1105-1063
100th anniversary of Robert Koch's Nobel Prize for the discovery of the tubercle bacillus 10.1016/j.tim.2005.08.003
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin 10.1172/JCI24617
Inter-laboratory validation of PCR-based detection of Mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissues 10.1007/s00428-005-1233-3
Ras-associated small GTPase 33A, a novel T cell factor, is down-regulated in patients with tuberculosis 10.1086/444428
Day of immunology: A far-reaching success [1] 10.1016/j.imlet.2005.06.018
A nutritive view on the host-pathogen interplay 10.1016/j.tim.2005.06.009
No life without death - Apoptosis as prerequisite for T cell activation 10.1007/s10495-005-2940-6
European day of immunology 10.1038/ni0805-741
Autistic effector T cells in mice with a point mutation in the LAT adaptor fail to respond to Listeria monocytogenes infection 10.1093/intimm/dxh276
Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma 10.1086/430621
Decontamination with vaporized hydrogen peroxide is effective against Mycobacterium tuberculosis 10.1111/j.1472-765X.2005.01683.x
Mycobacterium tuberculosis and the host response 10.1084/jem.20050842
Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination 10.1016/j.jconrel.2005.02.004
Differential requirements for the chemokine receptor CCR7 in T cell activation during: Listeria monocytogenes infection 10.1084/jem.20041204
Improved protection by recombinant BCG 10.1016/j.micinf.2005.03.012
Introduction. Rational vaccine development against tuberculosis: "Those who don't remember the past are condemned to repeat it" 10.1016/j.micinf.2005.03.006
Scant activation of CD8 T cells by antigen loaded on heat shock protein 10.1002/eji.200425603
Modified immunohistological staining allows detection of Ziehl-Neelsen-negative Mycobacterium tuberculosis organisms and their precise localization in human tissue 10.1002/path.1728
Annulling a dangerous liaison: Vaccination strategies against AIDS and tuberculosis 10.1038/nm1221
Human α-defensins neutralize anthrax lethal toxin and protect against its fatal consequences 10.1073/pnas.0500508102
Variable outcome of experimental interferon-γ therapy of disseminated Bacillus Calmette-Guerin infection in two unrelated interleukin-12Rβ1- deficient Slovakian children 10.1007/s00431-004-1599-2
Antigen presentation and recognition in bacterial infections 10.1016/j.coi.2004.12.004
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis 10.1086/425931
Iron and microbial infection 10.1038/nrmicro1046
Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Δ yej Salmonella mutants induce superior CD8+ T-cell responses 10.1111/j.1462-5822.2004.00418.x
New issues in tuberculosis 10.1136/ard.2004.028258
Application of mycobacterial proteomics to vaccine design: Improved protection by Mycobactenum bovis BCG Prime-Rv3407 DNA boost vaccination against tuberculosis 10.1128/IAI.72.11.6471-6479.2004
Protein identification and tracking in two-dimensional electrophoretic gels by minimal protein identifiers 10.1002/pmic.200400908
CFP10 discriminates between nonacetylated and acelylated ESAT-6 of Mycobacterium tuberculosis by differential interaction 10.1002/pmic.200400906
Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif 10.1093/intimm/dxh155
Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung 10.1002/path.1628
Involvement of Mycobacterium smegmatis undecaprenyl phosphokinase in biofilm and smegma formation 10.1016/j.micinf.2004.05.011
Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection 10.1086/422394
Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles 10.1016/j.vaccine.2004.05.005
Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells 10.1073/pnas.0403787101
Apoptosis paves the detour path for CD8T cell activation against intracellular bacteria 10.1111/j.1462-5822.2004.00408.x
Vaccination against tuberculosis: Current status and future promise 10.1055/s-2004-829506
Web-accessible proteome databases for microbial research 10.1002/pmic.200300737
IIGP, a member of the IFN inducible and microbial defense mediating 47 kDa GTPase family, interacts with microtubule binding protein hook3 10.1242/jcs.01039
DNA vaccination with gp96-peptide fusion proteins induces protection against intracellular bacterial pathogen 10.1093/intimm/dxh064
Erratum: Saposin C is required for lipid presentation by human CD1b (Nature Immunology (2004) vol. 5 (169-174)) 10.1038/ni0304-344a
Protective T cell response against intracellular pathogens in the absence of toll-like receptor signaling via myeloid differentiation factor 88 10.1093/intimm/dxh047
Regulatory T cells and infection: Suppression revisited 10.1002/eji.200324578
Saposin C is required for lipid presentation by human CD1b 10.1038/ni1035
Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology 10.1074/mcp.M300074-MCP200
Antigen-specific CD8+ T cell responses in intestinal tissues during murine listeriosis 10.1016/j.micinf.2003.10.004
Exacerbated Colitis Associated with Elevated Levels of Activated CD4+ T Cells in TCRα Chain Transgenic Mice 10.1053/j.gastro.2003.10.062
Functionally active CD8αβ+ TCRγδ intestinal intraepithelial lymphocytes in athymic nu/nu mice 10.1093/intimm/dxh008
Towards simple artificial infectious systems 10.1016/j.molmed.2003.09.002
Glucose-regulated stress proteins and antibacterial immunity 10.1016/j.tim.2003.09.001
Cell-Wall Alterations as an Attribute of Mycobacterium tuberculosis in Latent Infection 10.1086/378563
Immunology of tuberculosis: Impact on the development of novel vaccines | Immunologie der tuberkulose: Konsequenzen für die impfstoffentwicklung 10.1007/s00108-003-1057-7
The RD1 proteins of Mycobacterium tuberculosis: Expression in Mycobacterium smegmatis and biochemical characterization 10.1016/S1286-4579(03)00205-3
Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines 10.1002/eji.200323956
Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis 10.1038/nm906
Liver NKT cells: An account of heterogeneity 10.1016/S1471-4906(03)00162-5
A short history of Robert Koch's fight against tuberculosis: Those who do not remember the past are condemned to repeat it 10.1016/S1472-9792(02)00064-1
Immune response to tuberculosis: Experimental animal models 10.1016/S1472-9792(02)00063-X
T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection 10.1128/IAI.71.6.3076-3087.2003
A dangerous liaison between two major killers: Mycobacterium tuberculosis and HIV target dendritic cells through DC-SIGN 10.1084/jem.20021964
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses 10.1084/jem.20011347
Correction of the iron overload defect in β-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis 10.1084/jem.20020897
Mycobacterial proteomes 10.1016/S0076-6879(02)58093-9
Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium 10.1073/pnas.212488699
Cultivation of Mycobacterium bovis BCG in bioreactors 10.1016/S0168-1656(02)00046-9
Promiscuous peptide recognition of an autoreactive CD8+ T-cell clone is responsible for autoimmune intestinal pathology 10.1006/jaut.2002.0592
MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines 10.1073/pnas.092141999
Link between organ-specific antigen processing by 20S proteasomes and CD8 + T cell-mediated autoimmunity 10.1084/jem.20011199
On the shoulders of giants 10.1016/S1286-4579(01)01535-0
Characterization of the murine T-lymphocyte response to Salmonella enterica serovar typhimurium infection 10.1128/IAI.70.1.199-203.2002
Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes 10.1128/IAI.69.12.7922-7926.2001
Introduction: Microbiology and immunology. Lessons learned from Salmonella 10.1016/S1286-4579(01)01498-8
Bacterial virulence, proinflammatory cytokines and host immunity: How to choose the appropriate Salmonella vaccine strain? 10.1016/S1286-4579(01)01486-1
Development of live recombinant vaccine candidates against tuberculosis 10.1080/003655401317074473
Introduction: From genome to function - Monitoring global responses in infectious diseases by interrogating the transcriptome and proteome 10.1016/S1286-4579(01)01438-1
The stress proteome of Enterococcus faecalis 10.1002/1522-2683(200108)22:14<2947::AID-ELPS2947>3.0.CO;2-K
Proteomics reveals open reading frames in Mycobacterium tuberculosis H37Rv not predicted by genomics 10.1128/IAI.69.9.5905-5907.2001
Prospects for better tuberculosis vaccines 10.1016/S1473-3099(01)00018-4
Immune responses to intracellular bacteria 10.1016/S0952-7915(00)00236-3
Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA 10.1016/S0264-410X(01)00109-8
MHC class la-restricted T cells partially account for β2-microglobulin-dependent resistance to Mycobacterium tuberculosis 10.1002/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R
gp96-peptide vaccination of mice against intracellular bacteria 10.1128/IAI.69.6.4164-4167.2001
The many faces of host responses to tuberculosis 10.1046/j.1365-2567.2001.01236.x
Contribution of MHC class I-dependent immune mechanisms induced by attenuated recombinant Salmonella typhimurium secreting superoxide dismutase to protection against murine listeriosis 10.1016/S0264-410X(01)00022-6
A critical role of T-cell receptor γ/δ cells in antibacterial protection in mice early in life 10.1053/jhep.2001.23504
Intracellular bacteria as targets and carriers for vaccination 10.1515/BC.2001.066
Recombinant attenuated bacteria for the delivery of subunit vaccines 10.1016/S0264-410X(00)00502-8
From evil to good: A cytolysin in vaccine development 10.1016/S0966-842X(00)01893-X
CD1 molecules and CD1-dependent T cells in bacterial infections: A link from innate to acquired immunity? 10.1006/smim.2000.0272
Secretion of different listeriolysin cognates by recombinant attenuated Salmonella typhimurium: Superior efficacy of haemolytic over non-haemolytic constructs after oral vaccination 10.1016/S1286-4579(00)01333-2
Participation of leukocyte function-associated antigen-1 and NK cells in the homing of thymic CD8+NKT cells to the liver 10.1002/1521-4141(200010)30:10<3049::AID-IMMU3049>3.0.CO;2-F
Immune response against Mycobacterium tuberculosis: Implications for vaccine development 10.1016/S0168-1656(00)00292-3
Delivery of protein antigens and DNA by virulence-attenuated strains of Salmonella typhimurium and Listeria monocytogenes 10.1016/S0168-1656(00)00293-5
Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
CD1 and CD1-restricted T cells in infections with intracellular bacteria 10.1016/S0966-842X(00)01829-1
PCR-based quantification of Pneumocystis carinii in in vitro systems 10.1016/S1286-4579(00)90358-7
Isolation of RNA from mycobacteria grown under in vitro and in vivo conditions 10.1016/S0378-1097(00)00138-5
Substantial in vivo proliferation of CD4+ and CD8+ T lymphocytes during secondary Listeria monocytogenes infection 10.1002/(SICI)1521-4141(200004)30:4<1053::AID-IMMU1053>3.0.CO;2-N
Helicobacter pylori infection in wild-type and cytokine-deficient C57BL/6 and BALB/c mouse mutants 10.1016/S1286-4579(00)00367-1
Protection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30-kDa antigen of Mycobacterium bovis BCG 10.1016/S0928-8244(99)00205-9
Differential tolerance induction by lipoarabinomannan and lipopolysaccharide in human macrophages 10.1016/S1286-4579(00)00319-1
Rapid neutrophil response controls fast-replicating intracellular bacteria but not slow-replicating Mycobacterium tuberculosis 10.1086/315278
Increased numbers of ESAT-6- and purified protein derivative-specific gamma interferon-producing cells in subclinical and active tuberculosis infection 10.1128/IAI.68.10.6073-6076.2000
Is the development of a new tuberculosis vaccine possible? 10.1038/79631
Participation of group 2 CD1 molecules in the control of murine tuberculosis 10.1016/S1286-4579(99)00248-8
Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin 10.1016/S1286-4579(99)80077-X
Development of novel tuberculosis vaccines 10.1016/S0764-4469(00)87192-9
Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: Towards functional genomics of microbial pathogens 10.1046/j.1365-2958.1999.01549.x
A dynamic two-dimensional polyacrylamide gel electrophoresis database: The mycobacterial proteome via internet 10.1002/(SICI)1522-2683(19990801)20:11<2172::AID-ELPS2172>3.0.CO;2-M
Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells 10.1016/S1074-7613(00)80110-7
Effect on parasite eradication of Pneumocystis carinii-specific antibodies produced in the presence or absence of CD4+ αβ T lymphocytes 10.1002/(SICI)1521-4141(199908)29:08<2464::AID-IMMU2464>3.0.CO;2-F
Phenotypically activated T lymphocytes in the peripheral blood of patients with tuberculosis 10.1086/314844
Killing vs suicide in antibacterial defence 10.1016/S0966-842X(98)01444-9
Delivery of DNA vaccines by attenuated intracellular bacteria 10.1016/S0167-5699(98)01431-5
Pneumocystis carinii pneumonia in mutant mice deficient in both TCRαβ and TCRγδ cells: Cytokine and antibody responses 10.1086/314607
Induction of IFN-γ-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin 10.1002/(SICI)1521-4141(199902)29:02<650::AID-IMMU650>3.0.CO;2-M
Cell-mediated immunity: Dealing a direct blow to pathogens 10.1016/S0960-9822(99)80059-1
Live antigen carriers as tools for improved anti-tuberculosis vaccines 10.1016/S0928-8244(98)00132-1
Introduction of protein or DNA delivered via recombinant Salmonella typhimurium into the major histocompatibility complex class I presentation pathway of macrophages 10.1016/S1286-4579(99)80001-X
Microbes and Infection: Editorial 10.1016/S1286-4579(99)80008-2
Impact of intracellular location of and antigen display by intracellular bacteria: Implications for vaccine development 10.1016/S0165-2478(98)00128-X
The gene cluster inlC2DE of Listeria monocytogenes contains additional new internalin genes and is important for virulence in mice 10.1007/s004380050880
Introduction: The immune response to infectious agents 10.1016/S0580-9517(08)70675-5
A novel PrfA-regulated chromosomal locus, which is specific for Listeria ivanovii, encodes two small, secreted internalins and contributes to virulence in mice 10.1046/j.1365-2958.1998.01076.x
Checkpoints in antibacterial immunity 10.1016/S0923-2494(99)80041-8
Differential chemokine response of murine macrophages stimulated with cytokines and infected with Listeria monocytogenes 10.1093/intimm/10.6.757
Immune responses to naturally acquiredd Pneumocystis carinii in gene disruption mutant mice 10.1016/S0923-2494(98)80766-9
Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes 10.1073/pnas.95.9.5299
Immunological basics of new vaccination strategies | Immunologische Grundlagen neuer Impfstrategien 10.1007/s001140050454
Influence of mycobacterial virulence and culture condition on γδ T cell activation 10.1006/mpat.1997.0187
Pneumocystis carinii and the immune response in disease 10.1016/S0966-842X(97)01204-3
Immunity to fungi 10.1016/S0923-2494(98)80751-7
CD8αα T cells in lesions of Listeria monocytogenes-infected β2m- deficient mice 10.1006/mpat.1997.0133
Alternative antigen processing pathways in anti-infective immunity 10.1016/S0952-7915(97)80096-9
Interleukin-4 and listeriosis 10.1111/j.1600-065X.1997.tb00995.x
The B cell repertoire of patients with rheumatoid arthritis: II. Increased frequencies of IgG+ and IgA+ B cells specific for mycobacterial heat-shock protein 60 or human type II collagen in synovial fluid and tissue 10.1002/art.1780400808
Antibacterial vaccines: Impact of antigen handling and immune response 10.1007/s001090050121
Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions 10.1093/intimm/9.5.713
Rational design of antituberculosis vaccines: Impact of antigen display and vaccine localization 10.1006/biol.1997.0079
TCR-mediated target cell lysis by CD4+NK1+ liver T lymphocytes 10.1093/intimm/9.4.563
Effects of IL-13 on murine listeriosis 10.1093/intimm/9.4.467
Abscess formation in Listeria monocytogenes-infected γδ T cell deficient mouse mutants involves αβ T cells 10.1006/mpat.1996.0095
Immunity to infection. Editorial overview 10.1016/S0952-7915(97)80094-5
Bacille Calmette Guerin and interleukin-12 down-modulate interleukin-4-producing CD4+ NK1+ T lymphocytes 10.1002/eji.1830270127
Immunity to intracellular bacteria 10.1016/S0923-2494(97)85211-X
Constitutive biological activity of thymus-independent TCR-α-β+ intestinal intraepithelial lymphocytes in TCR-α(-/-) gene disruption mice 10.1016/S0165-2478(96)02647-8
Salmonella enterica infection 10.1016/S0923-2494(97)85225-X
Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway 10.1016/S0378-1119(96)00424-6
Rapid determination of γδ T-cell stimulation by microfluorimetry 10.1016/S0165-2478(96)02623-5
Activation of natural killer cells by heat-killed Listeria monocytogenes requires additional signals from lymphoid cells 10.1016/0165-2478(96)02523-0
γ/δ and other unconventional T lymphocytes: What do they see and what do they do? 10.1073/pnas.93.6.2272
Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis 10.1073/pnas.93.4.1458
The superantigen exfoliative toxin induces cutaneous lymphocyte-associated antigen expression in peripheral human T lymphocytes 10.1016/0165-2478(95)02491-3
Stimulation of protective CD8+ T lymphocytes by vaccination with nonliving bacteria 10.1073/pnas.92.26.12389
Differential induction ofIL12 synthesis by Mycobacterium bovis BCG and Listeria monocytogenes 10.1016/0923-2494(96)83026-4
Impact of host genetic background on Bacillus Calmette-Guerin infection in naturally susceptible mice 10.1016/0165-2478(95)02449-2
Protective role of γ/δ T cells and α/β T cells in tuberculosis 10.1002/eji.1830251025
Control of thymus-independent intestinal intraepithelial lymphocytes by β2-microglobulin 10.1002/eji.1830250832
Frequencies of IFNγ- and IL-4-producing cells during mycobacterium bovis BCG infection in two genetically susceptible mouse strains: Role of α/β t cells and NK1.1 cells 10.1016/0165-2478(95)00009-T
Immune response to mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II deficient knock-out mice: Contribution of CD4 and CD8 T cells to acquired resistance 10.1002/eji.1830250211
Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology 10.1002/eji.1830250222
Nitric oxide production and mycobacterial growth inhibition by murine alveolar macrophages: The sequence of rIFN-γ stimulation and Mycobacterium bovis BCG infection determines macrophage activation 10.1016/0165-2478(94)00193-U
Immunity to intracellular microbial pathogens 10.1016/0167-5699(95)80151-0
Elongated peptides, not the predicted nonapeptide stimulate a major histocompatibility complex class I-restricted cytotoxic T lymphocyte clone with specificity for a bacterial heat shock protein 10.1002/eji.1830241237
Novel insights and new models in a time of rapid technological change 10.1016/0952-7915(94)90134-1
Bacterial and protozoal infections in genetically disrupted mice 10.1016/0952-7915(94)90135-X
Phosphate is essential for stimulation of Vγ9Vδ2 T lymphocytes by mycobacterial low molecular weight ligand 10.1002/eji.1830240826
Application of knockout mice to the experimental analysis of infections with bacteria and protozoa 10.1016/0966-842X(94)90628-9
Presentation of Listeria monocytogenes antigens by major histocompatibility complex class I molecules to CD8 cytotoxic T lymphocytes independent of listeriolysin secretion and virulence 10.1002/eji.1830240703
Prevention of autoimmune lysis by T cells with specificity for a heat shock protein by antisense oligonucleotide treatment 10.1073/pnas.91.11.5085
Hydrophobic interaction chromatography for the purification of cytolytic bacterial toxins 10.1016/0021-9673(94)89061-7
Localisation of human peripheral blood leukocytes after transfer to C.B-17 scid/scid mice 10.1016/0165-2478(93)90120-Q
Vaccination strategies against intracellular microbes 10.1016/0928-8244(93)90058-C
In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tubercolosis in mice 10.1007/BF00190265
Tuberculosis: A neglected disease strikes back 10.1016/0966-842X(93)90015-J
Human peripheral blood leukocytes transplanted on CB17 scid-scid mice are transferred to their offspring 10.1002/eji.1830220711
Heat shock proteins in health and disease 10.1007/BF02591650
Hydrophobic interaction chromatography for the purification of a mycobacterial heat shock protein of relative molecular mass 60,000 10.1016/0021-9673(91)85193-J
Role of T-cell subsets in bacterial infections 10.1016/0952-7915(91)90004-K
Interleukins, mycobacteria, and listeriae 10.1016/0732-8893(90)90014-M
Immunity to mycobacteria 10.1016/0923-2508(90)90108-3
Direct blotting with viable cells of protein mixtures separated by two-dimensional gel electrophoresis 10.1016/0022-1759(90)90366-4
Primary responses of human T cells to mycobacteria: a frequent set of γ/δ T cells are stimulated by protease-resistant ligands 10.1002/eji.1830200534
Antimycobacterial functions in bone-marrow-derived macrophages 10.1016/0923-2508(90)90038-R
Immunity to bacteria 10.1016/0952-7915(89)90141-6
Infection of phagocytic cells 10.1016/0952-7915(89)90096-4
T cell clones and their products: Experimental clues for the immunoprophylaxis and immunotherapy of intracellular bacterial infections? 10.1007/BF01641694
Basiswissen Immunologie 10.1007/978-3-642-40325-5
Mycobacterium tuberculosis in the Proteomics Era 10.1128/microbiolspec.mgm2-0020-2013
The BCG replacement vaccine VPM1002: from drawing board to clinical trial 10.1586/14760584.2014.905746
Lung-Residing Myeloid-derived Suppressors Display Dual Functionality in Murine Pulmonary Tuberculosis 10.1164/rccm.201405-0828oc
Immunologische Grundlagen der Infektabwehr 10.1016/b978-343721741-8.50006-4
Novel Vaccination Strategies against Tuberculosis 10.1002/3527601449.ch21
Bicentennial of the first vaccination by Edward Jenner 10.1515/9783110906660.vii
Immune Mechanisms of Protection 10.1128/9781555818357.ch24
Current & Emerging Diagnostics, Therapeutics & Vaccines for Tuberculosis 10.2217/9781780840222
Immunology of Infectious Diseases 10.1128/9781555817978
The Innate Immune Response to Infection 10.1128/9781555817671
The Immune Response to Infection 10.1128/9781555816872
T-Cell Paradigms in Parasitic and Bacterial Infections 10.1007/978-3-642-74983-4
The Grand Challenge for the Future 10.1007/3-7643-7381-4
Antikörper und ihre Antigene 10.1007/978-3-540-46362-7_9
Mononukleäre Phagozyten und antigenpräsentierende Zellen 10.1007/978-3-540-46362-7_14
Organe des Immunsystems 10.1007/978-3-540-46362-7_8
Haupt-Histokompatibilitäts-Komplex 10.1007/978-3-540-46362-7_12
Zellen des Immunsystems 10.1007/978-3-540-46362-7_7
Monoclonal T Cells and T-Cell Hybridomas with Antibacterial Activity 10.1016/b978-0-12-463001-7.50018-4
Immune Intervention Strategies against Tuberculosis 10.1128/9781555816872.ch45
The Immune Response to Infectious Agents 10.1016/s0580-9517(10)37001-2
Acquired Immunity against Bacteria 10.1128/9781555817978.ch15
Antigen-Antikörper-Reaktion: Grundlagen serologischer Methoden 10.1007/978-3-540-46362-7_11
DNA Delivery with Attenuated Intracellular Bacteria 10.1007/978-1-4615-0105-3_15
Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guérin $\Delta$ureC:: hly vaccine's superior protection against tuberculosis doi: 10.1093/infdis/jiu347
The human immune response to tuberculosis and its treatment: a view from the blood doi: 10.1111/imr.12269
Tuberculosis vaccines: Time for a global strategy DOI: 10.1126/scitranslmed.aaa4730
TRANSVAC research infrastructure--Results and lessons learned from the European network of vaccine research and development doi:10.1016/j.vaccine.2015.01.079
Comprehensive insights into transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing doi:10.1186/s12864-014-1197-2
Individual T Helper Cells Have a Quantitative Cytokine Memory doi:10.1016/j.immuni.2014.12.018
Perspectives on host adaptation in response to Mycobacterium tuberculosis: Modulation of inflammation doi:10.1016/j.smim.2014.10.002
Platelets direct monocyte differentiation into epithelioid-like multinucleated giant foam cells with suppressive capacity upon mycobacterial stimulation doi: 10.1093/infdis/jiu355
CXCL5 Drives Neutrophil Recruitment in TH17-Mediated GN doi: 10.1681/ASN.2013101061
Differential transcriptomic and metabolic profiles of M. africanum-and M. tuberculosis-infected patients after, but not before, drug treatment 10.1038/gene.2015.21
CXCL5 drives neutrophil recruitment in TH17-mediated GN 10.1681/ASN.2013101061
The recombinant BCG ΔureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation 10.1093/infdis/jiu675
Aeras-sponsored meeting reports: Aerosol TB vaccines, whole mycobacteria cell TB vaccines, and prevention of sustained Mycobacterium tuberculosis infection 10.1016/j.vaccine.2015.04.001
Molecular signatures for vaccine development 10.1016/j.vaccine.2015.03.075
High-throughput data analysis and data integration for vaccine trials 10.1016/j.vaccine.2015.04.096
A Mouse Model of Latent Tuberculosis Infection to Study Intervention Strategies to Prevent Reactivation 10.1371/journal.pone.0158849
Mycobacterium tuberculosis infection modulates adipose tissue biology 10.1371/journal.ppat.1006676
IL-36/LXR axis modulates cholesterol metabolism and immune defense to Mycobacterium tuberculosis 10.1038/s41598-018-19476-x
Identification of potential biomarkers of vaccine inflammation in mice 10.7554/eLife.46149
FX11 limits Mycobacterium tuberculosis growth and potentiates bactericidal activity of isoniazid through host-directed activity 10.1242/dmm.041954
Pregnancy has a minimal impact on the acute transcriptional signature to vaccination 10.1038/s41541-020-0177-6
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus 10.1172/JCI136288
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
Carlos Martin
Martin Carlos / RID: A-7283-2008
ORCID: 0000-0003-2993-5478
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials 10.1016/j.vaccine.2013.07.051
ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169
Global Study of IS6110 in a Successful Mycobacterium tuberculosis Strain: Clues for Deciphering Its Behavior and for Its Rapid Detection 10.1128/JCM.00970-13
Mapping IS6110 in high-copy number Mycobacterium tuberculosis strains shows specific insertion points in the Beijing genotype 10.1186/1471-2164-14-422
Recent developments in tuberculosis vaccines 10.1586/14760584.2013.856765
Attenuated Mycobacterium tuberculosis SO2 Vaccine Candidate Is Unable to Induce Cell Death 10.1371/journal.pone.0045213
Conspicuous multidrug-resistant Mycobacterium tuberculosis cluster strains do not trespass country borders in Latin America and Spain 10.1016/j.meegid.2011.06.006
Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG 10.1128/AAC.05946-11
IS-seq: a novel high throughput survey of in vivo IS6110 transposition in multiple Mycobacterium tuberculosis genomes 10.1186/1471-2164-13-249
Long-term molecular surveillance of multidrug-resistant tuberculosis in Spain 10.1016/j.meegid.2011.05.016
Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4 + T-cell memory 10.1002/eji.201141903
Rapid Test for Identification of a Highly Transmissible Mycobacterium tuberculosis Beijing Strain of Sub-Saharan Origin 10.1128/JCM.06314-11
Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007
The Transcriptional Regulatory Network of Mycobacterium tuberculosis 10.1371/journal.pone.0022178
Drug-resistant tuberculosis in the European Union: Opportunities and challenges for control 10.1016/j.tube.2010.03.008
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
Interactions of Attenuated Mycobacterium tuberculosis phoP Mutant with Human Macrophages 10.1371/journal.pone.0012978
Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant 10.1016/j.vaccine.2009.02.060
Multidrug-Resistant Mycobacterium tuberculosis Strain from Equatorial Guinea Detected in Spain 10.3201/eid1511.090449
MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques 10.1371/journal.pone.0005264
Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth 10.1128/AAC.00550-09
A point mutation in the two-component regulator PhoP-PhoR accounts for the absence of polyketide-derived acyltrehaloses but not that of phthiocerol dimycocerosates in Mycobacterium tuberculosis H37Ra 10.1128/JB.01465-07
Attenuated strains of Mycobacterium tuberculosis complex for laboratory and clinical use 10.1016/j.tube.2008.04.004
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials 10.1517/14712598.8.2.201
Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host 10.1016/j.vetmic.2007.11.038
PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence 10.1371/journal.pone.0003496
The Mycobacterium tuberculosis phoPR Operon Is Positively Autoregulated in the Virulent Strain H37Rv 10.1128/JB.00712-08
Transcriptional analysis of and resistance level conferred by the aminoglycoside acetyltransferase gene aac(2′)-Id from Mycobacterium smegmatis 10.1093/jac/dkm440
Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG 10.1093/jac/dkl510
Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain 10.1111/j.1365-2249.2006.03284.x
Multidrug-resistant Mycobacterium tuberculosis Beijing/W genotype in Venezuela 10.1099/jmm.0.47310-0
Recurrent tuberculosis from 1992 to 2004 in a metropolitan area 10.1183/09031936.00005107
Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum 10.1093/jac/dki436
Molecular characterisation of Mycobacterium tuberculosis isolates in the first national survey of anti-tuberculosis drug resistance from Venezuela 10.1186/1471-2180-6-90
Novel streptomycin resistance gene from Mycobacterium fortuitum 10.1128/AAC.00223-06
The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs 10.1016/j.vaccine.2006.03.017
The use of mutant mycobacteria as new vaccines to prevent tuberculosis 10.1016/j.tube.2006.01.022
The virulence-associated twocomponent PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis 10.1074/jbc.C500388200
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Molecular characterization of Mycobacterium tuberculosis complex isolates from wild ungulates in south-central Spain 10.1051/vetres:2004051
Revisiting the evolution of Mycobacterium bovis 10.1128/JB.187.18.6386-6395.2005
The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? 10.1183/09031936.05.00109904
IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks 10.1128/JCM.42.1.212-219.2004
Mycobacterium smegmatis displays the Mycobacterium tuberculosis virulence-related neutral red character when expressing the Rv0577 gene 10.1016/S0378-1097(04)00008-4
An essential role for phoP in Mycobacterium tuberculosis virulence 10.1046/j.1365-2958.2001.02500.x
Molecular approaches to tuberculosis 10.1046/j.1365-2958.2001.02652.x
TRANSPOSITION OF AN ANTIBIOTIC-RESISTANCE ELEMENT IN MYCOBACTERIA 10.1038/345739a0
A human dendritic cell-based in vitro model to assess Mycobacterium tuberculosis SO2 vaccine immunogenicity. http://dx.doi.org/10.14573/altex.1311041
A Specific Polymorphism in Mycobacterium tuberculosis H37Rv Causes Differential ESAT-6 Expression and Identifies WhiB6 as a Novel ESX-1 Component 10.1128/IAI.01824-14
Bim is a crucial regulator of apoptosis induced by Mycobacterium tuberculosis 10.1038/cddis.2014.313
Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111
Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice 10.1016/j.vaccine.2014.07.047
Pulmonary Mycobacterium bovis BCG Vaccination Confers Dose-Dependent Superior Protection Compared to That of Subcutaneous Vaccination 10.1128/CVI.00700-13
Single nucleotide polymorphism (SNP) analysis used for the phylogeny of the Mycobacterium tuberculosis complex based on a pyrosequencing assay 10.1186/1471-2180-14-21
The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis 10.1371/journal.ppat.1004183
Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis 10.1016/j.micinf.2005.06.011
Vaccination against tuberculosis | Vacunación frente a la tuberculosis 10.1016/S1696-2818(11)70027-0
Corrigendum to "Mapping of IS6110 insertion sites in Mycobacterium bovis isolates in relation to adaptation from the animal to human host" [Vet. Microbiol. 129 (2008) 333-341] (DOI:10.1016/j.vetmic.2007.11.038) 10.1016/j.vetmic.2009.01.010
Unsuspected and extensive transmission of a drug-susceptible Mycobacterium tuberculosis strain 10.1186/1471-2466-9-3
Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity 10.1016/j.micinf.2008.10.013
Epidemiology of tuberculosis on Gran Canaria: A 4 year population study using traditional and molecular approaches 10.1136/thorax.58.7.618
Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis 10.1097/00002030-199710000-00006
Use of conjugative and thermosensitive cloning vectors for transposon delivery to Mycobacterium smegmatis 10.1016/0378-1097(95)00032-Z
Onopordum nervosum as biomass source: Some aspects of its production and transformation by enzymatic hydrolysis 10.1016/0960-8524(93)90180-J
Analysis of the regions responsible for IS6110 RFLP in a single Mycobacterium tuberculosis strain 10.1016/0923-2508(92)90104-V
Factors that affect transposition mediated by the Tn21 transposase 10.1016/0147-619X(88)90007-8
Aminoglycoside-phosphotransferases APH(3′)-IV and APH(3′) synthesized by a strain of campylobacter coli 10.1093/jac/18.2.153
Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056
Evolutionary Landscape of the Mycobacterium tuberculosis Complex from the Viewpoint of PhoPR: Implications for Virulence Regulation and Application to Vaccine Development 10.1128/mBio.01289-15
In Vivo IS6110 Profile Changes in a Mycobacterium tuberculosis Strain as Determined by Tracking over 14 Years 10.1128/JCM.00607-15
Klebsiella pneumoniae survives within macrophages by avoiding delivery to lysosomes 10.1111/cmi.12466
Nonspecific Beneficial Effects of BCG Vaccination in High-income Countries, Should We Extend Recommendation of BCG Vaccination? 10.1093/cid/civ148
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial 10.1016/S2213-2600(15)00435-X
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice 10.1016/j.tube.2015.10.010
In-depth analysis of the genome sequence of a clinical, extensively drug-resistant Mycobacterium bovis strain 10.1016/j.tube.2016.06.005
Tuberculosis vaccines: Past, present and future 10.1002/ajh.20459
New tuberculosis vaccines 10.1016/S0213-005X(11)70019-2
Granzyme a is expressed in mouse lungs during mycobacterium tuberculosis infection but does not contribute to protection in vivo 10.1371/journal.pone.0153028
Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology 10.1186/1471-2180-6-23
On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines 10.7717/peerj.1513
Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism 10.1093/infdis/jiv503
Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain 10.1128/JCM.43.3.1220-1227.2005
ESX-1-induced apoptosis during mycobacterial infection: To be or not to be, that is the question 10.3389/fcimb.2013.00088
Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and Mycobacterium tuberculosis 10.1128/AAC.45.3.800-804.2001
Evaluation of the immunogenicity and diagnostic interference caused by M-tuberculosis SO2 vaccination against tuberculosis in goats 10.1016/j.rvsc.2015.09.017
Construction of a family of Mycobacterium/Escherichia coli shuttle vectors derived from pAL5000 and pACYC184: Their use for cloning an antibiotic-resistance gene from Mycobacterium fortuitum 10.1016/0378-1119(96)00202-8
Detection of a Putative TetR-Like Gene Related to Mycobacterium bovis BCG Growth in Cholesterol Using a gfp-Transposon Mutagenesis System 10.3389/fmicb.2017.00315
MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. 10.1080/14760584.2017.1324303
Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. 10.1093/infdis/jix030
Mycobacterial diversity causing multi- and extensively drug-resistant tuberculosis in Djibouti, Horn of Africa 10.5588/ijtld.15.0268
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice. 10.3791/54440
Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines 10.1093/infdis/jiw228
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis 10.1038/ncomms16085
Breaking Transmission with Vaccines: The Case of Tuberculosis. 10.1128/microbiolspec.MTBP-0001-2016
Evaluation of the Mycobacterium tuberculosis SO2 vaccine using a natural tuberculosis infection model in goats 10.1016/j.tvjl.2017.04.006
MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic 10.3389/fimmu.2017.01803
Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures 10.1073/pnas.1720606115
New insights into the transposition mechanisms of IS6110 and its dynamic distribution between Mycobacterium tuberculosis Complex lineages 10.1371/journal.pgen.1007282
Vaccination against tuberculosis. 10.1016/j.eimc.2018.02.006
A Mycobacterium tuberculosis Beijing strain persists at high rates and extends its geographic boundaries 20 years after importation 10.1038/s41598-019-40525-6
Mycobacterium tuberculosis infection prevents asthma and abrogates eosinophilopoiesis in an experimental model 10.1111/all.13923
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines 10.1038/s41467-019-13387-9
Update on TB Vaccine Pipeline 10.3390/app10072632
Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential 10.1016/j.ebiom.2020.102761
New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia 10.1371/journal.ppat.1008404
Independent genomic polymorphisms in the PknH serine threonine kinase locus during evolution of the Mycobacterium tuberculosis Complex affect virulence and host preference 10.1371/journal.ppat.1009061
Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environment. 10.1016/j.ebiom.2020.103186
MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. 10.1038/s41541-020-00262-8
Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. 10.1016/j.xcrm.2020.100185
Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. 10.1016/j.xcrm.2020.100187
MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG 10.1016/j.vaccine.2021.06.049
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675
High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. 10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. 10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483
Kris Huygen
Huygen Kris
ORCID: 0000-0001-7808-0512
Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015. 10.1017/s0950268817001108
Field performance of six Mycobacterium avium subsp. paratuberculosis antigens in a 20h interferon gamma release assay in Belgium. 10.1016/j.vetimm.2017.05.008
Investigation of inflammatory and allergic responses to common mold species: Results from in vitro experiments, from a mouse model of asthma, and from a group of asthmatic patients. 10.1111/ina.12385
Trend analysis suggested a change in subspecies among Mycobacterium avium isolated from pigs in Belgium, 1967-2013. 10.1136/vr.103951
Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium. 10.1080/21505594.2017.1296998
Virulence and immunogenicity of genetically defined human and porcine isolates of M. avium subsp. hominissuis in an experimental mouse infection. 10.1371/journal.pone.0171895
The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam. 10.1093/cid/ciw551
Development of a Dot-Blot Assay for the Detection of Mould-Specific IgE in the Belgian Population. 10.1007/s11046-016-0091-7
Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of Mycobacterium tuberculosis. 10.1159/000450955
Correction: Capture-Recapture Estimators in Epidemiology with Applications to Pertussis and Pneumococcal Invasive Disease Surveillance. 10.1371/journal.pone.0165351
Capture-Recapture Estimators in Epidemiology with Applications to Pertussis and Pneumococcal Invasive Disease Surveillance. 10.1371/journal.pone.0159832
Mycobacterium tuberculosis-associated synthetic mycolates differentially exert immune stimulatory adjuvant activity. 10.1002/eji.201646357
Genome Sequences of Four Strains of Mycobacterium avium subsp. hominissuis, Isolated from Swine and Humans, Differing in Virulence in a Murine Intranasal Infection Model. 10.1128/genomea.00533-16
Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines. 10.1080/14760584.2016.1187067
Development of human monoclonal antibodies to diphtheria toxin: A solution for the increasing lack of equine DAT for therapeutic use? 10.1080/21505594.2016.1190062
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. 10.3390/vaccines4020016
Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. 10.1016/j.vaccine.2016.04.066
Serodiagnosis of whooping cough in Belgium: results of the National Reference Centre for Bordetella pertussis anno 2013. 10.1080/17843286.2015.1105607
Synthesis and anti-tubercular activity of N(2)-arylbenzo[g]isoquinoline-5,10-dione-3-iminium bromides. 10.1039/c5ob02138c
Genotyping and strain distribution of Mycobacterium avium subspecies hominissuis isolated from humans and pigs in Belgium, 2011-2013. 10.2807/1560-7917.es.2016.21.3.30111
Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study. 10.1016/j.vaccine.2015.10.100
Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. 10.1016/j.vaccine.2015.10.098
Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care. 10.3399/bjgp15x686917
In silico epitope analysis of unique and membrane associated proteins from Mycobacterium avium subsp. paratuberculosis for immunogenicity and vaccine evaluation. 10.1016/j.jtbi.2015.08.003
Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. 10.1016/j.vaccine.2015.06.108
Increased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis Antigen. 10.1371/journal.pone.0132288
Overexpression of DosR in Mycobacterium tuberculosis does not affect aerobic replication in vitro or in murine macrophages 10.1007/s13213-014-0910-3
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. 10.1016/s2213-2600(15)00037-5
DNA vaccines against tuberculosis. 10.1517/14712598.2014.951630
The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis. 10.3389/fimmu.2014.00321
Novel GMO-Based Vaccines against Tuberculosis: State of the Art and Biosafety Considerations. 10.3390/vaccines2020463
1,2,3,4,8,9,10,11-octahydrobenzo[j]phenanthridine-7,12-diones as new leads against Mycobacterium tuberculosis. 10.1021/jm401735w
2,4-Dialkyl-8,9,10,11-tetrahydrobenzo[g]pyrimido[4,5-c]isoquinoline-1,3,7,12(2H,4H)-tetraones as new leads against Mycobacterium tuberculosis. 10.1016/j.ejmech.2014.03.024
Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen. 10.3390/vaccines2010181
Anti-mycobacterial activity of 1,3-diaryltriazenes. 10.1016/j.ejmech.2014.02.065
Biological evaluation of diazene derivatives as anti-tubercular compounds. 10.1016/j.ejmech.2013.12.057
Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice. 10.1371/journal.pntd.0002604
M.tuberculosis mutants lacking oxygenated mycolates show increased immunogenicity and protective efficacy as compared to M. bovis BCG vaccine in an experimental mouse model. 10.1371/journal.pone.0076442
Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. 10.1111/imm.12130
Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012. 10.1017/s0950268813002458
Synthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine. 10.1016/j.ejmech.2013.06.010
Use of Strep-tag II for rapid detection and purification of Mycobacterium tuberculosis recombinant antigens secreted by Streptomyces lividans. 10.1016/j.mimet.2013.06.004
Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. 10.1371/journal.pone.0063344
Biological evaluation of bisbenzaldehydes against four Mycobacterium species. 10.1016/j.ejmech.2013.03.023
Clinical value of IS6110-based loop-mediated isothermal amplification for detection of Mycobacterium tuberculosis complex in respiratory specimens. 10.1016/j.jinf.2013.02.005
Induction of the specific allergic immune response is independent of proteases from the fungus Alternaria alternata. 10.1002/eji.201242630
Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. 10.1016/j.vaccine.2012.12.034
Targeting the deep lungs, Poloxamer 407 and a CpG oligonucleotide optimize immune responses to Mycobacterium tuberculosis antigen 85A following pulmonary delivery. 10.1016/j.ejpb.2012.11.020
An update on vaccines for tuberculosis - there is more to it than just waning of BCG efficacy with time. 10.1517/14712598.2012.721768
Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. 10.1128/iai.00021-12
Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. 10.1371/journal.pone.0033406
1,4-diarylpiperazines and analogs as anti-tubercular agents: synthesis and biological evaluation. 10.1016/j.ejmech.2011.12.035
Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents. 10.1016/j.ejmech.2011.11.033
Buruli ulcer. 10.4161/hv.7.11.17751
Immunogenicity of eight Mycobacterium avium subsp. paratuberculosis specific antigens in DNA vaccinated and Map infected mice. 10.1016/j.vetimm.2011.10.012
Characterization of new Alternaria alternata--specific rat monoclonal antibodies. 10.1007/s11046-011-9466-y
Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines. 10.1016/j.micinf.2011.08.011
Pertussis serodiagnosis in Belgium from 1990 to 2009. 10.1128/cvi.00003-11
Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. 10.1002/emmm.201000125
Biochemical and immunological characterization of a cpn60.1 knockout mutant of Mycobacterium bovis BCG. 10.1099/mic.0.045120-0
Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice. 10.1128/cvi.00352-10
T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients suffering from tuberculosis and nontuberculous mycobacterial infections. 10.1155/2011/640309
Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells. 10.1016/j.vaccine.2010.01.031
Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis. 10.1128/cvi.00446-09
DNA vaccines against mycobacterial diseases. 10.1586/erv.09.87
A novel and more sensitive loop-mediated isothermal amplification assay targeting IS6110 for detection of Mycobacterium tuberculosis complex. 10.1016/j.micres.2009.05.001
Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. 10.1172/jci35288
Buruli ulcer disease: prospects for a vaccine. 10.1007/s00430-009-0109-6
PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. 10.1371/journal.pone.0003496
Development and validation of a triplex real-time PCR for rapid detection and specific identification of M. avium sub sp. paratuberculosis in faecal samples. 10.1016/j.vetmic.2008.09.087
Use of Mycobacterium avium subsp. paratuberculosis specific coding sequences for serodiagnosis of bovine paratuberculosis. 10.1016/j.vetmic.2008.09.065
Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). 10.1016/j.vaccine.2008.09.025
Creating hybrid proteins by insertion of exogenous peptides into permissive sites of a class A beta-lactamase. 10.1111/j.1742-4658.2008.06646.x
Vaccination against paratuberculosis. 10.1586/14760584.7.6.817
Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome. 10.1016/j.vaccine.2008.07.009
Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. 10.1371/journal.pntd.0000199
Genetic resistance of mice to Mycobacterium paratuberculosis is influenced by Slc11a1 at the early but not at the late stage of infection. 10.1128/iai.01137-07
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine co-expressing pro-apoptotic caspase-3. 10.1016/j.vaccine.2007.12.056
Comparison of IFN-gamma responses to mycobacterial antigens as markers of response to BCG vaccination. 10.1016/j.tube.2007.10.001
GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. 10.1111/j.1365-3024.2007.00961.x
Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. 10.1016/j.cell.2007.04.043
Cloning, sequencing, and cell surface expression pattern of bovine immunoreceptor NKG2D and adaptor molecules DAP10 and DAP12. 10.1007/s00251-007-0226-6
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A. 10.1016/j.imlet.2007.04.010
Chronic intranasal administration of mould spores or extracts to unsensitized mice leads to lung allergic inflammation, hyper-reactivity and remodelling. 10.1111/j.1365-2567.2007.02636.x
Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. 10.1128/iai.01999-06
Antigen discovery: a postgenomic approach to paratuberculosis diagnosis. 10.1002/pmic.200600988
A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. 10.1128/iai.01622-06
Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. 10.1128/iai.01137-06
Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3. 10.1111/j.1365-2567.2006.02373.x
DNA vaccines against mycobacterial diseases. 10.2217/17460913.1.1.63
3rd annual DNA vaccines forum. 10.2217/17460913.1.1.17
Development of luminescent Mycobacterium avium subsp. paratuberculosis for rapid screening of vaccine candidates in mice. 10.1128/iai.01521-05
Partial reconstitution of the CD4+-T-cell compartment in CD4 gene knockout mice restores responses to tuberculosis DNA vaccines. 10.1128/iai.74.5.2751-2759.2006
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. 10.1016/j.vaccine.2005.12.066
Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. 10.1128/iai.74.2.1416-1418.2006
Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. 10.1128/iai.74.1.202-212.2006
Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model. 10.1196/annals.1352.030
Evaluation of the immunogenicity of pBudCE4.1 plasmids encoding mycolyl-transferase Ag85A and phosphate transport receptor PstS-3 from Mycobacterium tuberculosis. 10.1016/j.vaccine.2005.08.035
DNA vaccination for the priming of neutralizing antibodies against non-immunogenic STa enterotoxin from enterotoxigenic Escherichia coli. 10.1016/j.vaccine.2004.11.080
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. 10.1371/journal.pmed.0020108
Plasmid DNA vaccination. 10.1016/j.micinf.2005.03.010
Mycobacterium tuberculosis with disruption in genes encoding the phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo virulence. 10.1128/iai.73.3.1898-1902.2005
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. 10.1086/425931
Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. 10.4049/jimmunol.173.10.6357
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. 10.1038/nm1128
Antimycobacterial activity of synthetic pamamycins. 10.1093/jac/dkh402
Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin. 10.1111/j.1365-2567.2004.01903.x
Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis. 10.4049/jimmunol.172.11.6913
Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. 10.1126/science.1099384
Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. 10.1128/iai.72.2.958-965.2004
Prospects for vaccine development against Buruli disease. 10.1586/14760584.2.4.561
Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults. 10.1128/cdli.10.4.602-611.2003
A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. 10.1046/j.1365-2249.2003.02171.x
Pulmonary necrosis resulting from DNA vaccination against tuberculosis. 10.1128/iai.71.4.2192-2198.2003
On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. 10.1128/iai.71.4.1613-1621.2003
DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. 10.1046/j.1365-3083.2003.01218.x
Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment. 10.1016/s1472-9792(03)00054-4
Mapping of murine Th1 helper T-Cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. 10.1128/iai.71.1.483-493.2003
A GRA1 DNA vaccine primes cytolytic CD8(+) T cells to control acute Toxoplasma gondii infection. 10.1128/iai.71.1.309-316.2003
Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. 10.1016/s0264-410x(02)00289-x
IFN-gamma diagnostic tests in the context of bovine mycobacterial infections in Belgium. 10.1016/s0165-2427(02)00092-2
Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. 10.1097/00005392-199903000-00012
Characterization of the culture filtrate-specific cytotoxic T lymphocyte response induced by Bacillus Calmette-Guérin vaccination in H-2b mice. 10.1093/intimm/11.2.209
Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. 10.1054/tuld.1998.0196
Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy. 10.1097/00005392-199806000-00029
Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group. 10.1046/j.1365-3083.1997.d01-99.x
Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. 10.1046/j.1365-2249.1997.4141313.x
Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. 10.1016/s0264-410x(96)00274-5
Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. 10.1016/s0264-410x(96)00255-1
Three different putative phosphate transport receptors are encoded by the Mycobacterium tuberculosis genome and are present at the surface of Mycobacterium bovis BCG. 10.1128/jb.179.9.2900-2906.1997
A serine/threonine protein kinase from Mycobacterium tuberculosis. 10.1111/j.1432-1033.1997.00604.x
Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. 10.1097/00005392-199702000-00023
A Mycobacterium tuberculosis gene cluster encoding proteins of a phosphate transporter homologous to the Escherichia coli Pst system. 10.1016/0378-1119(96)00242-9
Identification of a second Mycobacterium tuberculosis gene cluster encoding proteins of an ABC phosphate transporter. 10.1016/0014-5793(96)00953-2
Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. 10.1038/nm0896-893
IgG humoral response against the antigen 85 complex homologues in leprosy. 10.1111/j.1365-3083.1994.tb03517.x
Detection of anti-85A and anti-85B IgG antibodies in HIV-infected patients with active pulmonary tuberculosis. 10.1007/bf01972010
T cell reactivity against antigen 85 but not against the 18- and 65-kD heat shock proteins in the early stages of acquired immunity against Mycobacterium leprae. 10.1111/j.1365-2249.1994.tb06235.x
Anti-renin T cells trigger normal B cells to produce anti-renin antibodies and normalize blood pressure in spontaneously hypertensive rats. 10.1093/intimm/5.12.1569
TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. 10.1002/eji.1830231208
Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia. 10.1002/ajh.2830430416
T-cell stimulation with purified mycobacterial antigens in patients and healthy subjects infected with Mycobacterium leprae: secreted antigen 85 is another immunodominant antigen. 10.1111/j.1365-3083.1993.tb01709.x
IL-6 production in response to purified mycobacterial heat-shock proteins and to antigen 85 in leprosy. 10.1006/cimm.1993.1112
The major secreted antigen complex (Ag 85) from Mycobacterium bovis bacille Calmette-Guérin is associated with protective T cells in leprosy: a follow-up study of 45 household contacts. 10.1093/infdis/167.5.1160
Absence of IgM and IgG antibody response to the three components of the Mycobacterium bovis BCG 85 complex antigen after BCG vaccination. 10.1378/chest.103.1.320-b
Isoelectrophoretic characterization of protein antigens present in mycobacterial culture filtrates and recognized by monoclonal antibodies directed against the Mycobacterium bovis BCG antigen 85 complex. 10.1111/j.1365-3083.1992.tb03130.x
The humoral immune response after BCG vaccination: an immunoblotting study using two purified antigens. 10.1016/0962-8479(92)90146-b
Peter Andersen
Andersen Peter
ORCID: 0000-0002-5869-2551
Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan 10.3389/fimmu.2018.00381
Unusual Self-Assembly of the Recombinant Chlamydia trachomatis Major Outer Membrane Protein–Based Fusion Antigen CTH522 Into Protein Nanoparticles 10.1016/j.xphs.2018.02.005
High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis 10.3389/fimmu.2017.01973
Seasonal Influenza Split Vaccines Confer Partial Cross-Protection against Heterologous Influenza Virus in Ferrets When Combined with the CAF01 Adjuvant 10.3389/fimmu.2017.01928
Protective Effect of Vaccine Promoted Neutralizing Antibodies against the Intracellular Pathogen Chlamydia trachomatis 10.3389/fimmu.2017.01652
A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522 10.1016/j.jconrel.2017.12.003
T Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties 10.1016/j.ebiom.2017.12.004
Systematic Investigation of the Role of Surfactant Composition and Choice of oil: Design of a Nanoemulsion-Based Adjuvant Inducing Concomitant Humoral and CD4+ T-Cell Responses 10.1007/s11095-017-2180-9
PO and ID BCG vaccination in humans induce distinct mucosal and systemic immune responses and CD4+ T cell transcriptomal molecular signatures 10.1038/mi.2017.67
Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract 10.3389/fimmu.2017.00569
Characterization of the Antigen-Specific CD4+ T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes 10.3389/fimmu.2015.00430
Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy 10.4049/jimmunol.1600965
Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6 10.1038/srep45969
Broadening CD4 + and CD8 + T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes 10.1128/jvi.00130-17
Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes 10.1371/journal.pone.0175707
An attenuated Mycobacterium tuberculosis clinical strain with a defect in ESX-1 secretion induces minimal host immune responses and pathology 10.1038/srep46666
Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection 10.1038/s41541-017-0011-y
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial 10.1016/s2213-2600(16)30436-2
The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge 10.1016/j.vaccine.2017.02.020
Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents 10.1093/cid/cix023
Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung 10.1038/mi.2016.70
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials 10.1016/j.vaccine.2017.01.055
Intrauterine inoculation of minipigs with Chlamydia trachomatis during diestrus establishes a longer lasting infection compared to vaginal inoculation during estrus 10.1016/j.micinf.2017.01.008
Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses 10.1038/mi.2016.28
H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial 10.1016/j.vaccine.2016.11.023
Age-Specific Adjuvant Synergy: Dual TLR7/8 and Mincle Activation of Human Newborn Dendritic Cells Enables Th1 Polarization 10.4049/jimmunol.1600282
Quantitative Protein Profiling ofChlamydia trachomatisGrowth Forms Reveals Defense Strategies Against Tryptophan Starvation 10.1074/mcp.m116.061986
Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants 10.1038/srep39097
Host immunity to Mycobacterium tuberculosis and risk of tuberculosis: A longitudinal study among Greenlanders 10.1016/j.vaccine.2016.09.047
Modulation of Primary Immune Response by Different Vaccine Adjuvants 10.3389/fimmu.2016.00427
Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing 10.1016/j.vaccine.2016.08.039
The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8 + T-cell responses: The immunological consequences of the biodistribution profile 10.1016/j.jconrel.2016.08.034
New tests for detection of Mycobacterium tuberculosis infection: sufficient to meet the WHO 2035 targets? 10.2217/fmb-2016-0131
Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis 10.1371/journal.pone.0161217
Genital tract lesions in sexually mature Göttingen minipigs during the initial stages of experimental vaginal infection with Chlamydia trachomatis serovar D 10.1186/s12917-016-0793-6
PET CT Identifies Reactivation Risk in Cynomolgus Macaques with Latent M. tuberculosis 10.1371/journal.ppat.1005739
Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection 10.1183/13993003.01464-2015
A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ+ CMI responses protects against a genital infection in minipigs 10.1038/icb.2015.79
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children 10.1038/srep22030
The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons 10.1016/j.immuni.2016.02.004
Reprogramming the T Cell Response to Tuberculosis 10.1016/j.it.2015.12.009
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens 10.1038/srep19570
Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis 10.3389/fimmu.2015.00628
Differential Influence of Nutrient-Starved Mycobacterium tuberculosis on Adaptive Immunity Results in Progressive Tuberculosis Disease and Pathology 10.1128/iai.01055-15
Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation 10.1016/j.vaccine.2015.09.024
TB vaccines; promoting rapid and durable protection in the lung 10.1016/j.coi.2015.06.001
Adaptive Immunity againstStreptococcus pyogenesin Adults Involves Increased IFN-γ and IgG3 Responses Compared with Children 10.4049/jimmunol.1500804
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial 10.1016/j.vaccine.2015.05.036
Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach 10.1016/j.jconrel.2015.05.004
Protein Energy Malnutrition during Vaccination Has Limited Influence on Vaccine Efficacy but Abolishes Immunity if Administered during Mycobacterium tuberculosis Infection 10.1128/iai.03030-14
Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+T Cells 10.1128/cvi.00092-15
Advanced Vaccine Research Methods for the Decade of Vaccines 10.21775/9781910190036
Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats 10.1016/j.vaccine.2015.02.011
Protection AgainstChlamydia trachomatisInfection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein 10.1093/infdis/jiv137
Human B cells produce chemokine CXCL10 in the presence of Mycobacterium tuberculosis specific T cells 10.1016/j.tube.2014.10.005
Protective CD4 T Cells Targeting Cryptic Epitopes of Mycobacterium tuberculosis Resist Infection-Driven Terminal Differentiation 10.4049/jimmunol.1300283
A stable nanoparticulate DDA/MMG formulation acts synergistically with CpG ODN 1826 to enhance the CD4+ T-cell response 10.2217/nnm.14.197
Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease 10.1016/j.vaccine.2010.10.022
An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines 10.1186/s12934-014-0162-8
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human 10.1016/j.vaccine.2014.10.036
Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial 10.1371/journal.pone.0114602
Characterization of protective immune responses promoted by human antigen targets in a urogenital Chlamydia trachomatis mouse model 10.1016/j.vaccine.2013.11.100
High-frequency vaccine-induced CD8+T cells specific for an epitope naturally processed during infection withMycobacterium tuberculosisdo not confer protection 10.1002/eji.201344358
Analysis of protein species differentiation among mycobacterial low-Mr-secreted proteins by narrow pH range Immobiline gel 2-DE-MALDI-MS 10.1016/j.jprot.2013.06.036
Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant 10.1016/j.vaccine.2014.05.050
Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics 10.1073/pnas.1314973111
Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 10.1371/journal.pone.0100879
Tuberculosis vaccines – rethinking the current paradigm 10.1016/j.it.2014.04.006
Novel Vaccination Strategies Against Tuberculosis 10.1002/9783527611614.ch31
Novel Vaccination Strategies against Tuberculosis 10.1101/cshperspect.a018523
The supramolecular structure is decisive for the immunostimulatory properties of synthetic analogues of a mycobacterial lipid in vitro 10.1039/c3ra42737d
Parasitic infection may be associated with discordant responses to QuantiFERON and tuberculin skin test in apparently healthy children and adolescents in a tuberculosis endemic setting, Ethiopia 10.1186/1471-2334-13-265
Cell-Mediated and Humoral Immune Responses after Immunization of Calves with a Recombinant Multiantigenic Mycobacterium avium subsp. paratuberculosis Subunit Vaccine at Different Ages 10.1128/cvi.05574-11
Therapeutic Vaccination Using Cationic Liposome-Adjuvanted HIV Type 1 Peptides Representing HLA-Supertype-Restricted Subdominant T Cell Epitopes: Safety, Immunogenicity, and Feasibility in Guinea-Bissau 10.1089/aid.2013.0076
Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1- IL-2-Secreting Central Memory Cells 10.4049/jimmunol.1300248
Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant 10.1371/journal.pone.0063575
Developing Solid Particulate Vaccine Adjuvants: Surface Bound Antigen Favours a Humoural Response, whereas Entrapped Antigen Shows a Tendency for Cell Mediated Immunity 10.2174/1567201811310030003
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection 10.1016/j.clim.2012.12.005
Designing CAF-adjuvanted dry powder vaccines: Spray drying preserves the adjuvant activity of CAF01 10.1016/j.jconrel.2013.01.031
ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination 10.1371/journal.pone.0080579
Bettering BCG: a tough task for a TB vaccine? 10.1038/nm.3153
Comparing Adjuvanted H28 and Modified Vaccinia Virus Ankara Expressing H28 in a Mouse and a Non-Human Primate Tuberculosis Model 10.1371/journal.pone.0072185
Proteomic Profiling ofMycobacterium tuberculosisIdentifies Nutrient-starvation-responsive Toxin–antitoxin Systems 10.1074/mcp.m112.018846
Faculty of 1000 evaluation for Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. 10.3410/f.718016188.793479629
Randomised Clinical Trial Investigating the Specificity of a Novel Skin Test (C-Tb) for Diagnosis of M. tuberculosis Infection 10.1371/journal.pone.0064215
Chlamydia muridarum T Cell Antigens and Adjuvants That Induce Protective Immunity in Mice 10.1128/iai.06338-11
Vaccine-Induced Th17 Cells Are Maintained Long-Term Postvaccination as a Distinct and Phenotypically Stable Memory Subset 10.1128/iai.00550-12
The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection 10.1172/jci46252
Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status 10.1586/erv.12.22
Synchronization of Dendritic Cell Activation and Antigen Exposure Is Required for the Induction of Th1/Th17 Responses 10.4049/jimmunol.1103183
A structurally informed autotransporter platform for efficient heterologous protein secretion and display 10.1186/1475-2859-11-85
CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice 10.1007/s00262-011-1156-6
A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog 10.1016/j.jconrel.2012.03.016
Deciphering the proteome of the in vivo diagnostic reagent “purified protein derivative” from Mycobacterium tuberculosis 10.1002/pmic.201100544
Immune Responses to ESAT-6 and CFP-10 by FASCIA and Multiplex Technology for Diagnosis of M. tuberculosis Infection; IP-10 Is a Promising Marker 10.1371/journal.pone.0043438
Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection 10.1016/j.jim.2011.05.008
The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity 10.1371/journal.pone.0039909
Increased Immunogenicity and Protective Efficacy of Influenza M2e Fused to a Tetramerizing Protein 10.1371/journal.pone.0046395
The hunt for a global killer 10.4161/hv.20886
A multistage tuberculosis vaccine that confers efficient protection before and after exposure 10.1038/nm.2285
Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers 10.1016/j.vaccine.2010.02.094
Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes 10.1016/j.vaccine.2011.06.040
Validation of the ALS Assay in Adult Patients with Culture Confirmed Pulmonary Tuberculosis 10.1371/journal.pone.0016425
Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens 10.1016/j.vaccine.2011.07.144
Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method 10.1016/j.jconrel.2010.11.021
Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo 10.1007/s11095-010-0301-9
Subunit Vaccines: Distearoylphosphatidylcholine-Based Liposomes Entrapping Antigen Offer a Neutral Alternative to Dimethyldioctadecylammonium-Based Cationic Liposomes as an Adjuvant Delivery System 10.1002/jps.22427
A New Experimental Infection Model in Ferrets Based on AerosolisedMycobacterium bovis 10.4061/2011/981410
CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets 10.1371/journal.pone.0022891
Immune Intervention Strategies against Tuberculosis 10.1128/9781555816872.ch45
Liposomal vaccine delivery systems 10.1517/17425247.2011.558081
Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome Retention Mediates Stronger Th1 Responses 10.1021/mp100208f
Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01 10.1016/j.vaccine.2011.07.025
Cationic liposomes as vaccine adjuvants 10.1586/14760584.6.5.785
Modulation of Cell Death byM. tuberculosisas a Strategy for Pathogen Survival 10.1155/2011/678570
Detection of bovine tuberculosis in herds with different disease prevalence and influence of paratuberculosis infection on PPDB and ESAT-6/CFP10 specificity 10.1016/j.prevetmed.2010.06.007
Adult-Like Anti-Mycobacterial T Cell and In Vivo Dendritic Cell Responses Following Neonatal Immunization with Ag85B-ESAT-6 in the IC31® Adjuvant 10.1371/journal.pone.0003683
Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31 10.1016/j.vaccine.2006.03.072
Antigenic Equivalence of Human T-Cell Responses to Mycobacterium tuberculosis-Specific RD1-Encoded Protein Antigens ESAT-6 and Culture Filtrate Protein 10 and to Mixtures of Synthetic Peptides 10.1128/iai.68.6.3314-3321.2000
Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose 10.1371/journal.pone.0005930
CD4 and CD8 T-Cell Responses to Mycobacterial Antigens in African Children 10.1164/rccm.200912-1862oc
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime–boost regimen 10.1016/j.vaccine.2009.10.114
Cutting Edge: Mincle Is Essential for Recognition and Adjuvanticity of the Mycobacterial Cord Factor and its Synthetic Analog Trehalose-Dibehenate 10.4049/jimmunol.0904013
First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses 10.4161/hv.6.12.13143
Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared with a Primary Intranasal Infection in a Mouse Genital Challenge Model 10.1371/journal.pone.0010768
Determining Adjuvant Activity on T-Cell Function In Vivo: Th Cells 10.1007/978-1-60761-585-9_15
T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection 10.1111/j.1365-2567.2009.03164.x
Potential role for ESAT6 in dissemination ofM. tuberculosisvia human lung epithelial cells 10.1111/j.1365-2958.2009.06959.x
Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response 10.1016/j.jconrel.2010.03.027
Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen 10.1016/j.jconrel.2009.10.022
Immunological Memory Transferred with CD4 T Cells Specific for Tuberculosis Antigens Ag85B-TB10.4: Persisting Antigen Enhances Protection 10.1371/journal.pone.0008272
Syringe Free Vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles Provides Strong and Prolonged Protection Against Tuberculosis 10.1371/journal.pone.0015043
CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations 10.1016/j.ijpharm.2009.10.043
Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis 10.1002/eji.200939830
Correction: Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis 10.1002/eji.201190009
First-in-Man Open Clinical Trial of a Combined rdESAT-6 and rCFP-10 Tuberculosis Specific Skin Test Reagent 10.1371/journal.pone.0011277
Double-blind randomized Phase I study comparing rdESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection 10.1016/j.tube.2007.11.004
Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status 10.1002/eji.200939856
TB vaccines: current status and future perspectives 10.1038/icb.2009.14
Adjuvanticity of a synthetic cord factor analogue for subunitMycobacterium tuberculosisvaccination requires FcRγ–Syk–Card9–dependent innate immune activation 10.1084/jem.20081445
Signal Regulatory Protein α (SIRPα)+ Cells in the Adaptive Response to ESAT-6/CFP-10 Protein of Tuberculous Mycobacteria 10.1371/journal.pone.0006414
Adjuvants Induce Distinct Immunological Phenotypes in a Bovine Tuberculosis Vaccine Model 10.1128/cvi.00229-09
Isolation of Mycobacterium avium Subspecies paratuberculosis Reactive CD4 T Cells from Intestinal Biopsies of Crohn's Disease Patients 10.1371/journal.pone.0005641
Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells 10.4049/jimmunol.0801592
Risk of sensitization in healthy adults following repeated administration of rdESAT-6 skin test reagent by the Mantoux injection technique 10.1016/j.tube.2008.09.007
Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin 10.1371/journal.pone.0006999
A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells 10.1371/journal.pone.0005771
Distinct Differences in the Expansion and Phenotype of TB10.4 Specific CD8 and CD4 T Cells after Infection with Mycobacterium tuberculosis 10.1371/journal.pone.0005928
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B–ESAT6 fusion protein 10.1016/j.vaccine.2009.09.007
Co-Infection of Cattle withFasciola hepaticaandMycobacterium bovis- Immunological Consequences 10.1111/j.1865-1682.2009.01075.x
Liposome-based cationic adjuvant formulations (CAF): Past, present, and future 10.1080/08982100902726820
Adjuvant properties of a simplified C32 monomycolyl glycerol analogue 10.1016/j.bmcl.2009.02.027
A Simple Mycobacterial Monomycolated Glycerol Lipid Has Potent Immunostimulatory Activity 10.4049/jimmunol.182.1.424
Novel Generation Mycobacterial Adjuvant Based on Liposome-Encapsulated Monomycoloyl Glycerol from Mycobacterium bovis Bacillus Calmette-Guerin 10.4049/jimmunol.0804091
ESAT-6/CFP10 Skin Test Predicts Disease in M. tuberculosis-Infected Guinea Pigs 10.1371/journal.pone.0001978
Ex Vivo Cytokine mRNA Levels Correlate with Changing Clinical Status of Ethiopian TB Patients and their Contacts Over Time 10.1371/journal.pone.0001522
Identification of Rv0222 from RD4 as a novel serodiagnostic target for tuberculosis 10.1016/j.tube.2007.12.001
Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants 10.1007/s10456-008-9121-5
PLGA microspheres for the delivery of a novel subunit TB vaccine 10.1080/10611860801900462
Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres 10.1080/10611860802228558
Protective anti-mycobacterial T cell responses through exquisitein vivo activation of vaccine-targeted dendritic cells 10.1002/eji.200737889
13 ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13
Liposome Delivery ofChlamydia muridarumMajor Outer Membrane Protein Primes a Th1 Response That Protects against Genital Chlamydial Infection in a Mouse Model1 10.1086/590670
Primary Activation of Antigen-Specific Naive CD4+ and CD8+ T Cells following Intranasal Vaccination with Recombinant Bacteria 10.1128/iai.00793-08
α,α′-trehalose 6,6′-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying 10.1016/j.bbamem.2008.01.013
NIR transmission spectroscopy for rapid determination of lipid and lyoprotector content in liposomal vaccine adjuvant system CAF01 10.1016/j.ejpb.2008.07.007
Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection 10.1111/j.1365-2567.2007.02751.x
Detecting a low prevalence of latent tuberculosis among health care workers in Denmark detected by M. tuberculosis specific IFN-γ whole-blood test 10.1080/00365540601148483
PrimaTB STAT-PAK Assay, a Novel, Rapid Lateral-Flow Test for Tuberculosis in Nonhuman Primates 10.1128/cvi.00230-07
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes 10.1111/j.1365-2567.2007.02560.x
Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)—A novel adjuvant inducing both strong CMI and antibody responses 10.1016/j.bbamem.2005.10.011
MHC class II Tetramer Guided Detection of Mycobacterium tuberculosis-specific CD4+T Cells in Peripheral Blood from Patients with Pulmonary Tuberculosis 10.1111/j.1365-3083.2007.01924.x
Evaluation of Mycobacterium tuberculosis-Specific Antibody Responses in Populations with Different Levels of Exposure from Tanzania, Ethiopia, Brazil, and Denmark 10.1086/520662
Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection 10.4049/jimmunol.178.6.3721
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major 10.1038/nm1592
Trehalose preserves DDA/TDB liposomes and their adjuvant effect during freeze-drying 10.1016/j.bbamem.2007.05.009
Induction of CD8 T Cells against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and the Presence of a Functional Region of Difference-1 10.4049/jimmunol.179.6.3973
The prognosis of latent tuberculosis: can disease be predicted? 10.1016/j.molmed.2007.03.004
Vaccine strategies against latent tuberculosis infection 10.1016/j.tim.2006.11.008
Tuberculosis vaccines — an update 10.1038/nrmicro1703
The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis 10.1128/iai.01290-06
Optimizing Antigen Cocktails for Detection of Mycobacterium bovis in Herds with Different Prevalences of Bovine Tuberculosis: ESAT6-CFP10 Mixture Shows Optimal Sensitivity and Specificity 10.1128/jcm.01184-06
Immune Responses to Defined Antigens of Mycobacterium bovis in Cattle Experimentally Infected with Mycobacterium kansasii 10.1128/cvi.00054-06
Early Antibody Responses to Experimental Mycobacterium bovis Infection of Cattle 10.1128/cvi.00061-06
A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice 10.1211/jpp.58.6.0009
Identification of CT521 as a Frequent Target of Th1 Cells in Patients with UrogenitalChlamydia trachomatisInfection 10.1086/508203
Tuberculosis in Elephants: Antibody Responses to Defined Antigens of Mycobacterium tuberculosis, Potential for Early Diagnosis, and Monitoring of Treatment 10.1128/cvi.00133-06
Use of Enzyme-Linked Immunospot Assay with Mycobacterium tuberculosis- Specific Peptides for Diagnosis of Recent Infection with M. tuberculosis after Accidental Laboratory Exposure 10.1128/jcm.44.3.1197-1201.2006
Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis 10.1016/j.micinf.2006.03.018
Novel overlapping coding sequences in Chlamydia trachomatis 10.1111/j.1574-6968.2006.00480.x
Prospects for a novel vaccine against tuberculosis 10.1016/j.vetmic.2005.11.030
TB vaccine strategies—What is needed to solve a complex problem? 10.1016/j.tube.2006.01.009
A novel TB vaccine; strategies to combat a complex pathogen 10.1016/s0165-2478(02)00232-8
Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guerin Immunity 10.4049/jimmunol.177.9.6353
The 6-Kilodalton Early Secreted Antigenic Target-Responsive, Asymptomatic Contacts of Tuberculosis Patients Express Elevated Levels of Interleukin-4 and Reduced Levels of Gamma Interferon 10.1128/iai.74.5.2817-2822.2006
Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis 10.1128/cvi.13.2.179-186.2006
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection againstMycobacterium tuberculosis 10.1002/eji.200636128
Cytokine profiles in tuberculosis patients and healthy subjects in response to complex and single antigens ofMycobacterium tuberculosis 10.1111/j.1574-695x.2006.00110.x
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model 10.1128/iai.72.10.6148-6150.2004
Assessing the Serodiagnostic Potential of 35 Mycobacterium tuberculosis Proteins and Identification of Four Novel Serological Antigens 10.1128/jcm.43.1.57-65.2005
Antibody Responses in Reindeer (Rangifer tarandus) Infected with Mycobacterium bovis 10.1128/cdli.12.6.727-735.2005
Diagnosis of latentMycobacterium tuberculosisinfection: is the demise of the Mantoux test imminent? 10.1586/14787210.3.6.981
Cationic Liposomes Containing Mycobacterial Lipids: a New Powerful Th1 Adjuvant System 10.1128/iai.73.9.5817-5826.2005
Prospective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Active Tuberculosis 10.1128/cdli.12.4.491-496.2005
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6 10.1016/j.vaccine.2004.11.051
Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6 10.1128/iai.69.5.2773-2778.2001
Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR 10.1016/j.jim.2005.01.013
Vaccines for Tuberculosis: Novel Concepts and Recent Progress 10.1128/cmr.18.4.687-702.2005
Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 10.4049/jimmunol.174.10.6332
ESAT‐6 and CFP‐10 in Clinical versus Environmental Isolates ofMycobacterium kansasii 10.1086/428950
The success and failure of BCG — implications for a novel tuberculosis vaccine 10.1038/nrmicro1211
TB subunit vaccines—putting the pieces together 10.1016/j.micinf.2005.03.013
Mapping Immune Reactivity toward Rv2653 and Rv2654: Two Novel Low‐Molecular‐Mass Antigens Found Specifically in theMycobacterium tuberculosisComplex 10.1086/381679
Antigen Recognition by Serum Antibodies in White-Tailed Deer (Odocoileus virginianus) Experimentally Infected with Mycobacterium bovis 10.1128/cdli.11.5.849-855.2004
TB diagnosis in non-human primates: comparison of two interferon-γ assays and the skin test for identification of Mycobacterium tuberculosis infection 10.1016/j.vetimm.2004.03.003
Characterization of a Mycobacterium tuberculosis Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles 10.4049/jimmunol.173.3.1966
Reactivation of Tuberculosis During Immunosuppressive Treatment in a Patient with a Positive QuantiFERON®-RD1 Test 10.1080/00365540410015222
The Influence of Remaining Live BCG Organisms in Vaccinated Mice on the Maintenance of Immunity to Tuberculosis 10.1111/j.0300-9475.2004.01471.x
CFP10 discriminates between nonacetylated and acetylated ESAT-6 ofMycobacterium tuberculosis by differential interaction 10.1002/9783527610099.ch8
CFP10 discriminates between nonacetylated and acetylated ESAT-6 ofMycobacterium tuberculosis by differential interaction 10.1002/pmic.200400906
Protein-Protein Interactions of Proteins from the ESAT-6 Family of Mycobacterium tuberculosis 10.1128/jb.186.8.2487-2491.2004
Association of Tuberculin-Boosted Antibody Responses with Pathology and Cell-Mediated Immunity in Cattle Vaccinated with Mycobacterium bovis BCG and Infected with M. bovis 10.1128/iai.72.5.2462-2467.2004
Recognition of ESAT-6 Sequences by Antibodies in Sera of Tuberculous Nonhuman Primates 10.1128/cdli.11.1.222-226.2004
Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines 10.1128/iai.72.3.1608-1617.2004
Comparative Analysis of Different Vaccine Constructs Expressing Defined Antigens fromMycobacterium tuberculosis 10.1086/425931
Healthy Individuals That Control a Latent Infection with Mycobacterium tuberculosis Express High Levels of Th1 Cytokines and the IL-4 Antagonist IL-4 2 10.4049/jimmunol.172.11.6938
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts 10.1164/rccm.200402-232oc
Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection 10.1128/jcm.42.6.2379-2387.2004
PPE Protein (Rv3873) from DNA Segment RD1 of Mycobacterium tuberculosis: Strong Recognition of Both Specific T-Cell Epitopes and Epitopes Conserved within the PPE Family 10.1128/iai.71.11.6116-6123.2003
Genomic Approach to Identification of Mycobacterium bovis Diagnostic Antigens in Cattle 10.1128/jcm.41.8.3719-3728.2003
The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection 10.1007/s00431-003-1199-6
Specific Delayed-Type Hypersensitivity Responses to ESAT-6 Identify Tuberculosis-Infected Cattle 10.1128/jcm.41.5.1856-1860.2003
Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights 10.2174/1389201033377931
Human Th1 Cell Lines Recognize the Mycobacterium tuberculosis ESAT-6 Antigen and its Peptides in Association with Frequently Expressed HLA Class II Molecules 10.1046/j.1365-3083.2003.01204.x
Improved serodetection of Mycobacterium bovis infection in badgers (Meles meles) using multiantigen test formats 10.1016/s0732-8893(03)00046-4
Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak 10.1016/s0140-6736(03)12950-9
Use of mycobacterial peptides and recombinant proteins for the diagnosis of bovine tuberculosis in skin test-positive cattle 10.1136/vr.153.20.615
Gamma Interferon Responses Induced by a Panel of Recombinant and Purified Mycobacterial Antigens in Healthy, Non-Mycobacterium bovis BCG-Vaccinated Malawian Young Adults 10.1128/cdli.10.4.602-611.2003
Restoration of mycobacterial antigen-induced proliferation and interferon-γ responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy 10.1016/s0928-8244(03)00166-4
Human T-cell responses to the RD1-encoded protein TB27.4 (Rv3878) from Mycobacterium tuberculosis 10.1111/j.1365-2567.2003.01763.x
Responses of Bovine WC1+   T Cells to Protein and Nonprotein Antigens of Mycobacterium bovis 10.1128/iai.70.11.6114-6120.2002
Effect of different adjuvants on the immune responses of cattle vaccinated with Mycobacterium tuberculosis culture filtrate proteins 10.1016/s0165-2427(02)00017-x
Preparation of Culture Filtrate Proteins from Mycobacterium tuberculosis 10.1385/1-59259-147-7:205
Epitope Mapping of the Immunodominant Antigen TB10.4 and the Two Homologous Proteins TB10.3 and TB12.9, Which Constitute a Subfamily of the esat-6 Gene Family 10.1128/iai.70.10.5446-5453.2002
Hypoxic Response of Mycobacterium tuberculosis Studied by Metabolic Labeling and Proteome Analysis of Cellular and Extracellular Proteins 10.1128/jb.184.13.3485-3491.2002
Evaluation of a New Commercial Assay for Diagnosis of Pulmonary and Nonpulmonary Tuberculosis 10.1007/s10096-002-0737-x
Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection with Mycobacterium tuberculosis 10.1128/iai.70.6.3111-3121.2002
Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients 10.1128/jcm.40.2.704-706.2002
Tuberculosis subunit vaccine development: on the role of interferon-γ 10.1016/s0264-410x(00)00519-3
Tuberculosis vaccine development 10.1097/00063198-200205000-00006
Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis 10.1128/iai.70.2.672-678.2002
Specific Acquired Resistance in Mice Immunized with Killed Mycobacteria 10.1046/j.1365-3083.2002.01152.x
A novel TB vaccine; towards a strategy based on our understanding of BCG failure 10.1016/s0264-410x(02)00447-4
Long‐Lived Immune Response to Early Secretory Antigenic Target 6 in Individuals Who Had Recovered from Tuberculosis 10.1086/323044
Tuberculosis Contacts but Not Patients Have Higher Gamma Interferon Responses to ESAT-6 than Do Community Controls in The Gambia 10.1128/iai.69.10.6554-6557.2001
Towards more accurate diagnosis of bovine tuberculosis using defined antigens 10.1054/tube.2000.0273
Use of ESAT‐6 and CFP‐10 Antigens for Diagnosis of Extrapulmonary Tuberculosis 10.1086/317663
Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA 10.1016/s0264-410x(01)00109-8
Antigen Discovery and Tuberculosis Vaccine Development in the Post-genomic Era 10.1080/003655401753382639
Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation 10.1046/j.1365-2567.2001.01305.x
Interleukin-6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine 10.1046/j.1365-2567.2001.01244.x
Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research 10.1073/pnas.201404898
Use of ESAT-6 in the interferon-γ test for diagnosis of bovine tuberculosis following skin testing 10.1016/s0378-1135(00)00375-8
Tuberculin Skin Testing Compared with T-Cell Responses to Mycobacterium tuberculosis-Specific and Nonspecific Antigens for Detection of Latent Infection in Persons with Recent Tuberculosis Contact 10.1128/cdli.8.6.1089-1096.2001
TB vaccines: progress and problems 10.1016/s1471-4906(01)01865-8
High Resolution Electroelution of Polyacrylamide Gels for the Purification of Single Proteins from Mycobacterium tuberculosis Culture Filtrate 10.1046/j.1365-3083.2000.00655.x
Diagnosis of Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10 10.1128/cdli.7.2.155-160.2000
Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells 10.1002/1521-4141(200012)30:12<3689::aid-immu3689>3.3.co;2-w
Comparative Evaluation of Low-Molecular-Mass Proteins from Mycobacterium tuberculosis Identifies Members of the ESAT-6 Family as Immunodominant T-Cell Antigens 10.1128/iai.68.1.214-220.2000
Mapping and identification ofMycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection 10.1002/(sici)1522-2683(20000301)21:5<935::aid-elps935>3.0.co;2-p
Towards the proteome of Mycobacterium tuberculosis 10.1002/1522-2683(200011)21:17<3740::aid-elps3740>3.3.co;2-v
Assessment of defined antigens for the diagnosis of bovine tuberculosis in skin test-reactor cattle 10.1136/vr.146.23.659
ESAT-6 Subunit Vaccination against Mycobacterium tuberculosis 10.1128/iai.68.2.791-795.2000
Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen 10.1002/1521-4141(200006)30:6<1724::aid-immu1724>3.0.co;2-a
Multiple Epitopes from the Mycobacterium tuberculosis ESAT-6 Antigen Are Recognized by Antigen-Specific Human T Cell Lines 10.1086/313862
Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85 10.1016/s1286-4579(00)01323-x
Tuberculosis vaccines: developmental work and the future 10.1097/00063198-200005000-00007
Detection of Active Tuberculosis Infection by T Cell Responses to Early‐Secreted Antigenic Target 6‐kDa Protein and Culture Filtrate Protein 10 10.1086/315448
CD4+ T-Cell Subsets That Mediate Immunological Memory to Mycobacterium tuberculosis Infection in Mice 10.1128/iai.68.2.621-629.2000
Specific immune-based diagnosis of tuberculosis 10.1016/s0140-6736(00)02742-2
Immunological evaluation of novel Mycobacterium tuberculosis culture filtrate proteins 10.1016/s0928-8244(98)00129-1
Human T Cell Responses to the ESAT‐6 Antigen fromMycobacterium tuberculosis 10.1086/314640
Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree 10.1054/tuld.1999.0206
tuberculin purified protein derivative 10.18578/bnfc.732616164
Analysis of T cells recruited during delayed-type hypersensitivity to purified protein derivative (PPD) versus challenge with tuberculosis infection 10.1046/j.1365-2567.1998.00561.x
Comparison of Antigen-Specific T-Cell Responses of Tuberculosis Patients using Complex or Single Antigens ofMycobacterium tuberculosis 10.1046/j.1365-3083.1998.00419.x
Human cytolytic and interferon  -secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis 10.1073/pnas.95.1.270
Immunity to Mycobacteria with Emphasis on Tuberculosis: Implications for Rational Design of an Effective Tuberculosis Vaccine 10.1159/000058699
A Mycobacterium tuberculosis operon encoding ESAT=6 and a novel low-molecular-mass culture filtrate protein (CFP-10) 10.1099/00221287-144-11-3195
Secreted Antigens and Immune Responses to Mycobacterium tuberculosis 10.1159/000157430
The Potential of the ESAT-6 Antigen Secreted by Virulent Mycobacteria for Specific Diagnosis of Tuberculosis 10.1086/593686
Host Responses and Antigens Involved in Protective Immunity to Mycobacterium tuberculosis 10.1046/j.1365-3083.1997.d01-380.x
Report of the Expert Panel IX Vaccines against tuberculosis 10.1016/s0264-410x(96)90051-1
Key epitopes on the secreted ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis 10.1016/s0165-2478(97)88663-4
The T Cell Response to Secreted Antigens of Mycobacterium tuberculosis 10.1016/s0171-2985(11)80460-2
T Cell Response to Mycobacterium tuberculosis 10.1093/infdis/167.6.1481
Simultaneous electroelution of whole SDS-polyacrylamide gels for the direct cellular analysis of complex protein mixtures 10.1016/0022-1759(93)90195-d
Identification of Immunodominant Antigens during Infection with Mycobacterium tuberculosis 10.1111/j.1365-3083.1992.tb03144.x
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis 10.1016/j.chom.2017.05.012
Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder 10.1016/j.vaccine.2018.04.055
Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C) 10.3389/fimmu.2018.00898
Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System 10.3389/fimmu.2018.00380
Development of a proof of concept immunochromatographic lateral flow assay for point of care diagnosis of Mycobacterium tuberculosis 10.1186/1756-0500-6-202
CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination 10.1371/journal.pone.0005139
Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis 10.4049/jimmunol.0900947
A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice 10.1371/journal.pone.0006950
Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements 10.1371/journal.pone.0003116
A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts 10.3389/fimmu.2018.00661
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development 10.3389/fimmu.2017.01203
Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting 10.3389/fimmu.2018.01248
Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine 10.1016/0264-410x(93)90289-a
Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves 10.1371/journal.pone.0201253
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination 10.1056/nejmoa1714021
Dose Optimization of H56:IC31 Vaccine for TB Endemic Populations: A Double-Blind, Placebo-Controlled, Dose-Selection Trial 10.1164/rccm.201802-0366oc
C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial 10.1371/journal.pone.0204554
Concurrent infection with Mycobacterium tuberculosis confers robust protection against secondary infection in macaques 10.1101/403691
Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization 10.3389/fimmu.2018.02825
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo 10.3791/57554
Immunocorrelates of CAF family adjuvants 10.1016/j.smim.2018.10.003
A Liposome Based Adjuvant Containing Two Delivery Systems with the Ability to Induce Mucosal Immunoglobulin A Following a Parenteral Immunization 10.1021/acsnano.8b05209
Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial 10.5588/ijtld.18.0137
Diagnostic accuracy of ESAT-6 free IGRA compared to QuantiFERON-TB Gold In-tube 10.1093/cid/ciz034
Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection 10.1038/s41385-019-0145-5
Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration 10.1016/j.ejpb.2019.04.020
Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to M. Tuberculosis Infection 10.3389/fimmu.2019.00934
Moving tuberculosis vaccines from theory to practice 10.1038/s41577-019-0174-z
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice 10.1038/s42003-019-0530-3
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial 10.1016/s1473-3099(19)30279-8
Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers 10.1016/j.celrep.2019.07.047
Site-Specific DC Surface Signatures Influence CD4+ T Cell Co-stimulation and Lung-Homing 10.3389/fimmu.2019.01650
Metabolic profiling and compound-class identification reveal alterations in serum triglyceride levels in mice immunized with human vaccine adjuvant Alum 10.1021/acs.jproteome.9b00517
Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles 10.1021/acs.molpharmaceut.9b00908
Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming 10.1016/j.vaccine.2019.10.047
HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen 10.1038/s41598-019-50365-z
Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge 10.1038/s41541-020-0157-x
Gunilla Källenius
Källenius Gunilla
ORCID: 0000-0002-8921-0551
African 2, a Clonal Complex of Mycobacterium bovis Epidemiologically Important in East Africa 10.1128/JB.00750-10
A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab ')(2) fragment prolong survival of mice infected with Mycobacterium tuberculosis 10.1111/j.1365-2249.2004.02593.x
European 1: A globally important clonal complex of Mycobacterium bovis 10.1016/j.meegid.2011.04.027
MLVA Based Classification of Mycobacterium tuberculosis Complex Lineages for a Robust Phylogeographic Snapshot of Its Worldwide Molecular Diversity 10.1371/journal.pone.0041991
Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis 10.1016/S0264-410X(03)00274-3
Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions 10.1099/mic.0.27284-0
Mycobacterial glycoconjugates as vaccine candidates against tuberculosis 10.1016/j.tim.2008.07.007
The Guinea-Bissau Family of Mycobacterium tuberculosis Complex Revisited 10.1371/journal.pone.0018601
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda 10.1186/1471-2334-13-88
Mycobacterium tuberculosis strains potentially involved in the TB epidemic in Sweden a century ago 10.1371/journal.pone.0046848
Detection of proliferative responses to ESAT-6 and CFP-10 by FASCIA assay for diagnosis of Mycobacterium tuberculosis infection 10.1016/j.jim.2011.05.008
The relationship between disease pattern and disease burden by chest radiography, M-tuberculosis load, and HIV status in patients with pulmonary tuberculosis in Addis Ababa 10.1007/s15010-004-3089-x
Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine (TM) L3 adjuvant protects against tuberculosis 10.1016/j.vacinne.2003.10.016
Evaluation of outpatients with suspected pulmonary tuberculosis in a high HIV prevalence setting in Ethiopia: Clinical, diagnostic and epidemiological characteristics 10.1080/00365540110080025
Molecular epidemiology of drug-resistant tuberculosis in Sweden 10.1016/j.micinf.2008.03.006
Failure To Recruit Anti-Inflammatory CD103(+) Dendritic Cells and a Diminished CD4(+) Foxp3(+) Regulatory T Cell Pool in Mice That Display Excessive Lung Inflammation and Increased Susceptibility to Mycobacterium tuberculosis 10.1128/IAI.05552-11
Tuberculosis and HIV Co-Infection 10.1371/journal.ppat.1002464
Drug Resistant Mycobacterium tuberculosis of the Beijing Genotype Does Not Spread in Sweden 10.1371/journal.pone.0010893
Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells and enhance their ability to mediate HIV transinfection 10.1002/eji.201142049
Genomic Stability over 9 Years of an Isoniazid Resistant Mycobacterium tuberculosis Outbreak Strain in Sweden 10.1371/journal.pone.0016647
Characterization of Mycobacterium tuberculosis Central Asian Strain I using mycobacterial interspersed repetitive unit genotyping 10.1186/1471-2180-7-76
Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker 10.1371/journal.pone.0043438
Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice 10.1016/j.tube.2004.09.013
Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in peri-urban Kampala, Uganda 10.1186/1471-2334-8-101
Genetic diversity in clinical isolates of Mycobacterium avium complex from Guinea-Bissau, West Africa 10.1016/j.micinf.2004.07.007
The mtp40 gene is not present in Mycobacterium bovis 10.1054/tube.2002.0338
African 1, an Epidemiologically Important Clonal Complex of Mycobacterium bovis Dominant in Mali, Nigeria, Cameroon, and Chad 10.1128/JB.01590-08
Mycobacterium tuberculosis Strains Are Differentially Recognized by TLRs with an Impact on the Immune Response 10.1371/journal.pone.0067277
Should a new tuberculosis vaccine be administered intranasally? 10.1016/j.tube.2006.12.006
Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique 10.1186/1471-2180-10-195
Mycobacterium tuberculosis Beijing genotype is associated with HIV infection in Mozambique 10.1371/journal.pone.0071999
Genetic characterization of the Guinea-Bissau family of Mycobacterium tuberculosis complex strains 10.1016/j.micinf.2003.12.006
DNA restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from HIV-seropositive and HIV-seronegative patients in Kampala, Uganda 10.1186/1471-2334-9-12
Prevalence of bovine tuberculosis and risk factor assessment in cattle in rural livestock areas of Govuro District in the Southeast of Mozambique 10.1371/journal.pone.0091527
Biomarkers for tuberculosis: the case for lipoarabinomannan 10.1183/23120541.00115-2018
A new mathematical model to identify contacts with recent and remote latent tuberculosis 10.1183/23120541.00078-2019
Summary of the Sussex-Huawei locomotion-transportation recognition challenge
Observation of a manifold in the chaotic phase space of an asymmetric optical microcavity
Localized temporal variation of Earth's inner-core boundary from high-quality waveform doublets
Off-axis multi-wavelength dispersion controlling metalens for multi-color imaging
Impact of United States political sanctions on international collaborations and research in Iran